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Abstract
Parkinson’s disease (PD) is associated with reduced dopaminergic (DA) input to the
dorsal striatum (DS). This study investigated the role of DA in modulating automatic, stimulusdriven reactions by assessing contextual control of stimulus-locked responses (SLRs) in 10 PD
patients off and on DA medication. The SLR is the rapid recruitment of limb muscles that drives
the arm towards suddenly appearing stimuli. Participants reached away from (anti-reach) or
towards (pro-reach) a target on a screen, depending on instruction appearing 500 or 1000 ms
before target appearance. Modulation of SLRs was assessed by comparing SLR magnitude on
anti- and pro-reach trials using surface electrodes. We predicted patients would exhibit less
modulation of the SLR while off medication, especially with only 500 ms of instruction. Patients
modulated the SLR less with 500ms of instruction, but there was no effect of medication state,
suggesting modulation of the SLR is independent of DA input to the DS.

Keywords: Parkinson’s disease, Dopamine, Dorsal striatum, Visuomotor, Stimulus-locked
response, Superior colliculus

iii

Summary for Lay Audience
Parkinson’s disease (PD) is a movement disorder best known for its motor symptoms
such as bradykinesia (slowness of movement), tremor, rigidity, and freezing of gait.
Paradoxically, PD impairs the ability to initiate voluntary movement, but leaves automatic
movements triggered by external targets (e.g. quickly reaching towards a moving object) intact
and uninhibited. PD is associated with significant death of the cells responsible for producing
dopamine (DA) molecules in the brain pathway to the dorsal striatum (DS), the input region to
the basal ganglia (BG). The BG are a set of nuclei in the brain that modulate movement by
regulating opposing activating and inhibitory signals to various brain structures involved in
movement. This study aimed to investigate the ability of PD patients to contextually control fast
visuomotor responses by assessing their modulation of the stimulus-locked response (SLR). The
SLR is the earliest wave of arm muscle activity in response to a suddenly appearing target, that
always drives the arm towards the target. The contextual control of the SLR was measured by
comparing the magnitude of the response when the participants were instructed to reach away
from the target (anti-reach) to when they were instructed to reach towards it (pro-reach). The
colour of a square on the screen indicated whether it was an anti- or pro-reach trial either 500 ms
or 1000 ms before the target appeared. Participants completed one session off their DA
medication, and one session on their medication. We found that the ability to modulate the SLR
was improved when participants had a longer instructional cue. However, even when the task
was most challenging with only 500 ms to process the instructional cue, there was no difference
in the contextual control of the SLR off and on medication. Overall, this suggests that the ability
to generate and control the SLR is unaffected by the DA deficit in PD, however data from a
healthy control group is needed to confirm this conclusion.
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Chapter 1
1

Introduction

1.1 Parkinson’s disease
1.1.1 Aetiology and Pathology
Parkinson’s disease (PD) is a prevalent movement disorder, widely recognized by slowed
voluntary movement, tremor, rigidity, and freezing of gait. The incidence of PD increases
sharply over the age of 65 years old and is most often the result of a combination of genetic and
environmental factors (Lill & Klein, 2017). PD is classified as a neurodegenerative disease due
to the progressive loss of dopaminergic neurons in midbrain structures. At the time of symptom
onset, more than 50% of the dopaminergic neurons in the substantia nigra pars compacta (SNc)
have degenerated, resulting in dopamine (DA) depletion in the downstream basal ganglia (BG;
Cheng et al., 2010). Pathological dysfunction of the BG circuitry results in the manifestation of
hallmark motor, cognitive, and emotional deficits.

The BG are a network of subcortical nuclei which receive afferent projections from the
cortex, thalamus, SNc, and ventral tegmental area (VTA) via the dorsal striatum (DS; Squire et
al., 2012). The primary output regions of the BG are the substantia nigra pars reticulata (SNr)
and the internal segment of the globus pallidus (GPi), which send inhibitory gammaaminobutyric acid (GABA)ergic projections to various downstream targets involved in
movement and cognition. The BG circuitry relies on dopaminergic input from the nigrostriatal
pathway to precisely regulate activity of two opposing pathways involved in modulating this
inhibitory output: the direct and indirect pathways (Obeso et al., 2008). Dopaminergic input from
the nigrostriatal pathway is taken up by D1 and D2 receptors on medium spiny neurons (MSN)
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in the DS. Importantly, DA has excitatory post-synaptic effects on D1 receptors, and inhibitory
effects on D2 receptors (Obeso et al., 2008; Fuxe et al., 2006). MSNs constituting the origin of
the direct pathway predominantly express D1 receptors and are therefore activated upon
dopaminergic input. In contrast, MSNs of the indirect pathway predominantly express D2
receptors and are hyperpolarized by DA. This antagonistic mechanism is critical for behavioural
modulation, because the direct and indirect pathways have opposing influence on BG output to
various structures, including the motor nuclei of the superior colliculi and thalamus, which
ultimately modulates the cortex (Figure 1; DeLong & Wichmann, 2015; Terao et al., 2017). The
direct pathway is composed of GABAergic connections from the DS to the GPi and SNr.
Because the efferent projections from the SNr and GPi to the SC and thalamus are inhibitory, the
direct pathway promotes action initiation by releasing the motor neurons in the SC, and the
excitatory signals to the cortex via the thalamus, from tonic inhibition. The indirect pathway has
the opposite effect. Inhibitory projections from the DS to the external segment of the globus
pallidus (GPe) supress the inhibitory projections from the GPe to the subthalamic nucleus (STN),
which in turn increases glutaminergic activation of the SNr and GPi, and therefore increases net
inhibitory output to target structures. In PD, dopaminergic cell death in the nigrostriatal pathway
disrupts the balance between the direct and indirect circuits due to a decrease in activation of the
direct pathway, and a lack of inhibition of the indirect pathway. Behaviourally, the effect of the
denervated striatum translates to a variety of cognitive, affective, and motor impairments.
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Figure 1 Schematic of the basal ganglia circuitry. The direct pathway is downregulated in Parkinson's disease
and the indirect pathway is upregulated.

1.1.2 Motor Symptoms of PD

Motor symptoms of PD include bradykinesia (i.e., slowness of movement),
akinesia/hypokinesia (i.e., reduced number and amplitude of movements), tremor, rigidity, and
freezing of gait (Jankovic, 2008, Moustafa et al., 2016). Bradykinesia and akinesia are among the
first symptoms to appear in PD and are well-evidenced in studies of reaction times. Compared to
healthy controls, PD patients have significantly longer reaction times, especially in the absence
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of an external stimulus to elicit or guide the movement (i.e., internally-guided movements)
(Berardelli et al., 2001). Patients exhibit slower movements, with reduced velocity and
acceleration, as well as decreased magnitude of motions (e.g., smaller reaches, abnormally small
hand writing). Akinesia/hypokinesia is demonstrated by difficulty initiating volitional
movements, as well as a loss or reduction of spontaneous movements, such as arm swinging
while walking and facial expressions (Mardsen, 1989). Electromyography (EMG) studies have
identified abnormalities in the muscle activity of PD patients performing volitional actions.
Specifically, movement-related EMG activity is reduced relative to that of healthy controls, and
rises more slowly after onset, which results in the muscle taking longer to generate sufficient
force to initiate movement (Berardelli et al, 2001). An EMG study investigating recruitment of
the biceps muscles reported that simple elbow flexions were significantly slower than those of
controls, and there was no increase in co-contraction of agonist muscles, suggesting the deficit
was caused by an impairment in the ability to recruit the participating agonist muscle efficiently
(Beradelli et al., 1986). Hallett and Khoshbin (1980) demonstrated that in comparison to the
typical triphasic EMG bursts preceding fast movements, the first burst of EMG activity is
significantly smaller in PD patients, which is accompanied by additional cycles of bursts to
compensate. Reduced muscle recruitment is not the result of weakness, as PD patients are able to
increase the strength of muscle activity with more demanding tasks, but the problem lies in the
ability to appropriately scale their muscle recruitment to task demands compared to controls
(Berardelli et al., 1986).

Tremor is a very common symptom of PD, and at least 70% of patients present a tremor
during some point of disease progression (Helmich et al., 2012). In PD, tremor generally occurs
only at rest or with greater frequency and amplitude at rest compared to during the maintenance
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of a posture or performance of an action (Moustafa et al., 2016). Rigidity refers to the subjective
feeling of stiffness, as well as an increased resistance to passively or actively moving muscles,
limbs, the neck, or trunk. Rigidity also leads to common (e.g., stooped posture), as well as
uncommon (e.g., pisa syndrome in which patients lean) postural abnormalities. Nearly
universally, PD patients present with a stooped posture caused by neck flexion, rounding of the
shoulders, as well as flexion at the hips, which causes patients to lean forward. Less commonly,
patients might lean to one side quite noticeably, referred to as the Pisa Syndrome (Jankovic,
2008). Freezing of gait and postural instability significantly impact the independence and quality
of life of patients. Freezing of gait refers to the feeling that the feet are stuck to the floor.
Patients with freezing of gait have difficulty and hesitancy in initiating walking, as well as abrupt
cessation of stepping during ambulation. Patients with freezing of gait have greater variability in
stepping, frequently producing tiny, hesitant steps as well as complete cessation. It tends to
manifest more often in crowded places and narrow environments. Freezing of gait significantly
increases the patient’s risk of falling.

1.1.3 Dopamine Therapies for PD
Although there is no cure or neuroprotective therapies available for PD, symptoms are
commonly and effectively treated with exogenous supplementation of DA. L-3,4dihydroxyphenylalanine (levodopa), the metabolic precursor to DA, is the standard
pharmacological treatment of the motor symptoms of PD (Davie, 2008; Fahn & Poewe, 2015). It
is administered orally in conjunction with carbidopa, a peripheral decarboxylase inhibitor, to
prevent the premature conversion of levodopa to DA by aromatic L-amino acid decarboxylase
before levodopa crosses the blood-brain barrier (Muller, 2013). This greatly improves the
bioavailability of orally administered levodopa in the brain, as DA itself cannot pass the blood
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brain barrier, and therefore cannot reach the SNc if converted in the peripheral nervous system
(LeWitt, 2015). Once in the SNc, levodopa is metabolized, which effectively replenishes DA to a
functional level, thereby correcting the imbalance between activation of the direct and indirect
BG pathways (Hood et al., 2007). Levodopa has a half-life of 60-90 minutes and is typically
taken multiple times per day to maintain sufficient DA supply to the DS, the brain region that is
first and most significantly DA depleted in PD (Salat & Tolosa). Alternatively, motor symptoms
are treated with oral administration of DA agonists, which act by mimicking DA and stimulating
post-synaptic DA receptors in the brain, and similarly restore function to the DS, which is
reciprocally connected to most of the cerebral cortex.

1.2 Fast Visuomotor Responses
1.2.1 Fast Visuomotor Responses in PD
A seemingly paradoxical, but increasingly evident feature of Parkinson’s disease (PD) is
the preservation of fast visuomotor responses alongside the significant deficits in volitional
movement. This is apparent in the results of Merritt et al. (2017), which demonstrate the ability
of PD patients to produce extremely rapid alterations to reach trajectories mid-movement. The
study employed a pointing paradigm in which participants were instructed to point to a visual
target, which unexpectedly jumped to a new location during the saccadic eye movement towards
the target on some trials. PD patients were able to make appropriate online adjustments to the
trajectory of their reach when the target was suddenly displaced, regardless of whether the target
jump was consciously perceived. Additionally, the modification of the reach trajectory was
performed at the same point in the movement by PD patients and healthy controls. These results
suggest that the ability to rapidly transform visual information into short-latency (~100
ms) motor commands is unaffected by PD.
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The results of Merritt et al. (2017) contradict the previously reported findings of
Desmurget and colleagues (2004) who tested online reach corrections in a traditional double-step
paradigm, in which participants were instructed to reach towards a target that was unexpectedly
displaced to a new location upon hand movement onset. They found PD patients were unable to
modify their ongoing reach when the target was displaced compared to healthy controls, as
patients made more errors on the task, and took longer to adjust their reach in response to target
displacement. The discrepancies in the results of these two studies can likely be explained by the
failure of Desmurget et al. (2004) to account for the confounding effect of bradykinesia on the
length of the preparatory period preceding the start of the reach. Because target displacement
was triggered by hand movement onset, participants with longer reach reaction times had an
extended period of time to program their reach trajectory towards the target’s original location.
The length of time between initial target onset and target displacement has been shown to
affect participants’ ability to modify the reach in young healthy populations (Komilis et al.,
1993; Liu & Todorov, 2007; Sarlegna & Mutha, 2015). Consequently, the paradigm employed
by Desmurget et al. (2004) inherently favored participants with shorter reaction times and
rendered PD patients at a significant disadvantage. Conversely, the paradigm used by Merritt et
al. (2017) successfully controlled for the effect of bradykinetic reaction times in the PD group by
having target displacement triggered by saccadic eye movement, rather than hand movement,
which did not differ between PD and control participants.
The finding that fast, automatic adjustments to reach trajectory are generated with the
same speed and precision in PD patients and healthy controls is congruent with the hypothesized
role of the dorsal striatum (DS) in the modulation of automatic movements. Functional magnetic
resonance imaging (fMRI) studies have linked DS activity to the suppression of automatic
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responses in favour of the task-appropriate response (Cools, 2006; Ali et al., 2010; Liu et al.,
2010; Zandbelt et al., 2013). Accordingly, DS dysfunction in PD is strongly associated with
hyper-automaticity and difficulty suppressing reactions towards salient stimuli (Jahanshahi et al.,
2015). The tendency for PD patients to perform the more automatic response over responses
requiring greater control has been thoroughly documented in studies of cognition (Brown &
Marsden, 1988; Henik et al., 1993; Dujardin et al., 1999), and is more recently becoming
apparent in studies of motor control. Specifically, PD patients make more errors on tests of
reaction inhibition, such as the stop-signal reaction time test and go-no-go test (Obeso et al.,
2008; Gauggel et al., 2004; Beste et al., 2010).
Failed inhibition of visuomotor activation in PD is demonstrated in the findings of
Praamstra et al. (2001), who studied the effect of spatial stimulus-response compatibility (i.e.,
the Simon Effect; Simon, 1990) on reaction times of PD patients and healthy controls. The
Simon Effect describes the tendency of participants to respond more quickly when the direction
or location of the response corresponds to the location of the appearing visual stimulus. Shorter
reaction times on trials in which the appropriate response and the stimulus are on the same side
of the display are thought to be the result of a more automatic, stimulus-driven motor pathway,
whereas responses on the opposite side to the stimulus are thought to be mediated by a more
cognitively controlled pathway. Actions mediated by the volitional motor pathway are
susceptible to interference from stimulus-driven responses, yielding longer reaction times
(Kornblum et al., 1990). Praamstra et al. (2001) employed a paradigm in which a cue to respond
with either the left or right hand suddenly appeared in a box on either the left or right side of the
screen. Responses were made by squeezing the left or right hand on manipulanda according to
the instructional cue. The effect of stimulus-response compatibility, measured as the difference
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between reaction times on stimulus-response compatible vs incompatible trials, was greater for
patients with PD than healthy controls. Further, patients made more directional errors than
controls on stimulus-response incompatible trials. Therefore, inhibition of the tendency to
respond on the side of the visual stimulus was comparatively impaired in the PD group.
Additionally, PD patients consistently differ from healthy controls on oculomotor tasks.
When patients are instructed to look towards a stimulus target when it appears (pro-saccade),
they make more short-latency (90-140ms) express saccades than age-matched controls.
However, in the absence of a visual stimulus, the latencies of memory-guided saccades are either
delayed or undistinguishable from controls (Briand et al., 1999; Chan et al., 2005; Terao et al.,
2011; Lu et al., 2019). PD patients make more directional errors (i.e., saccades towards the
stimulus) and have longer saccadic reaction times on the anti-saccade task, in which they are
instructed to perform a saccade away from the stimulus or in the opposite direction from which it
appeared (Briand et al., 1999; Chan et al., 2005; Terao et al., 2011; Terao et al., 2013; Lu et al.,
2019). Moreover, when participants are instructed to keep their gaze directed at a fixation point
and refrain from making a saccade towards a visual stimulus when it appears, they have more
difficulty suppressing the automatic saccade towards the stimulus and make significantly more
errors than healthy controls (Hood et al., 2007). These tasks assess the ability to select between
competing automated stimulus-driven, and voluntary goal-driven responses. Together, these
findings suggest detrimental effects of DS dysfunction on the modulation of automatic
responses, resulting in intact and uninhibited fast visuomotor responses, but impaired controlled
visuomotor actions.
There are a variety of studies in the current literature highlighting a deficit in PD patients
when switching tasks from one to another (Lees & Smith 1983; Gauntlett-Gilbert et al., 1999;
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Dimitrov et al., 1999; Cools et al., 2001). Cameron et al. (2010) investigated whether the relative
automaticity of the two tasks influences this behavioural deficit and found that PD patients have
trouble switching tasks to a less automatic action but have an advantage over healthy controls
when switching to a more automatic action. Participants were instructed to focus their attention
on a fixation point, which was red or green to indicate an anti-saccade or pro-saccade trial
respectively. A target then appeared to the left or right of the fixation point, and participants
generated either an anti- or pro-saccade accordingly. On some trials, the colour of the fixation
point suddenly changed either just before, concurrent with, or just after target appearance,
making the participant change their response from a pro- to anti-saccade or from an anti- to prosaccade. On pro-to-anti trials PD patients made significantly more directional errors than healthy
controls, whereas on anti-to-pro saccade trials PD patients made fewer directional errors than
controls. Moreover, PD patients made fewer directional errors on anti-to-pro trials than on nonswitch anti-saccade trials, unlike controls who always performed better in the non-switch
condition. These results demonstrate the response bias towards the more habitual behaviour, and
the deficit in overriding automatic, but not volitional, oculomotor responses in patients with PD.

1.2.2 The Stimulus-Locked Response (SLR)
An empirical measure of output from the fast visuomotor pathway is the stimulus-locked
response (SLR). The SLR is the first burst of muscle activity that appears on neck and limb
muscles following the sudden appearance of a visual stimulus. Specifically, the appearance of
the SLR is well-documented in non-human primates and humans on dorsal neck muscles
involved in turning the head, and the pectoralis major and deltoid posterior muscles involved
in whole arm reaching (Pruszynski et al., 2010; Goonetilleke et al., 2015). This response is
detected as an excitatory or inhibitory change in EMG activity on agonist and antagonist muscles
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respectively, to orient the head or limbs towards the stimulus (Corneil et al., 2004; Pruszynski et
al., 2010; Chapman & Corneil, 2011; Gu et al., 2016). In reaching tasks in which participants are
instructed to reach towards a visual target as soon as it emerges, the SLR is apparent in EMG
activity within < 100 ms (Pruszynski et al., 2010; Gu et al., 2018).

1.2.3 SLR Magnitude, but not Latency or Directionality, is Influenced by Movement Goal
The defining feature of the SLR is its extremely short latency relative to stimulus
appearance (< 100 ms). On a trial-to-trial basis, the onset of the SLR is more time-locked to
stimulus onset, than to movement onset. This response is clearly distinct from the subsequent
muscle recruitment associated with voluntary reaching, as the latency of the SLR does not
change with variance in reaction time (Pruszynski at al., 2010), and is unaffected by task
complexity (Gu et al., 2018). The time required to initiate a volitional reaching action in response
to a visual stimulus (~200 ms) is much longer than the time required for visual information to
reach the cortex and the resulting motor command to reach the arm muscles via the corticospinal
tract, leaving time for cognitive processing and integration of pre-planned, top-down instruction
to modulate the action (Welford, 1980). Reaction times of voluntary movements are
consequently longer on more complex tasks due to increased cognitive processing time. In
contrast, Gu et al. (2018) demonstrated that increased complexity of reaching tasks, for example
by requiring subjects to move around or through objects to reach a target, has no influence
on SLR latency, despite increases in reach reaction times. Instead, such increases in task
complexity lead to reduced SLR magnitudes. Analogously, the latency and accuracy of online
reach corrections are unaffected by increased task complexity or simultaneous performance on a
cognitively demanding task (Liu et al., 2008; McIntosh et al., 2010). Therefore, a key
distinguishable feature between automatic visuomotor responses and volitional muscle
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recruitment is that the cognitive load required to prepare the planned motor goal has no influence
on the timing of the pathway linking visual information to the earliest phase of muscle
recruitment.
Functionally, the SLR facilitates rapid coordination of stimulus-targeted responses to our
complex and ever-changing environment. The strong negative correlation between SLR
magnitude on arm muscles and reaction times of reaches towards the stimulus implies a benefit
of automated muscle recruitment when the reaching goal corresponds to the location of the
stimulus (Pruszynski et al., 2010). However, with such short latencies, there is little time
between stimulus emergence and SLR onset for cognitive control or inhibition. In fact, on
behavioural tasks in which participants are instructed to either refrain from reaching, or reach
away from a target when it appears, the SLR remains directionally tuned to the target (Wood et
al., 2015; Gu et al., 2016; Atsma et al., 2018). In this way, regardless of task instruction, the
initial burst of muscle activity drives the arm towards the target. Consequently, in situations in
which the participant reaches in the opposite direction (i.e., anti-reach), there is a positive
correlation between SLR magnitude and reach reaction time, as the arm must overcome that
initial force driving the muscle towards the target before it initiates a reach in the opposite
direction (Gu et al., 2016). Interestingly, there is some influence of contextual factors on the
SLR, as evidenced by partial suppression of the SLR on anti-reach trials in healthy participants
(Gu et al., 2016). Relative to the magnitude of the SLR when participants reach towards a target
(i.e., pro-reach), the magnitude of the SLR preceding anti-reaches is dampened in favour of
behavioural flexibility. Despite its short latency and seemingly automatic nature, this suggests
the presence of nodes within the circuitry governing SLRs that convey information about
planned reach trajectory, and modulate SLR magnitude, but not latency or direction, accordingly.
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SLRs are evidently modulated differently than volitional reaches, but the neural substrates
involved in regulating this fast visuomotor pathway remain unclear.

1.2.4 Neural Substrates of SLR Generation and Modulation
The extremely short, stimulus-locked latency and directional tuning towards a visual
stimulus, rather than the instructed movement direction, suggests the neural pathway that
generates SLRs is separate from the corticospinal pathway that generates volitional movements.
This is further supported by ongoing studies in our lab that are finding the SLR is robustly intact
in PD patients, despite the significant effects of the disease on voluntary movement and
movement-related EMG activity. The SLR likely shares the same neural circuitry as shortlatency movement corrections performed mid-reach (Kozak et al., 2019), which are also
preserved in PD, as described above (Merritt et al., 2017).
Studies seeking to further elucidate the neural circuitry involved in fast visuomotor
responses have manipulated features of the stimuli used to elicit SLRs and online corrections, to
identify attributes that preferential evoke this pathway. SLRs are more prevalent on tasks with
moving targets than static targets (Kozak et al., 2020), and stronger in response to higher contrast
target stimuli (Wood, 2015; Kozak 2021). Additionally, Kozak and colleagues’ (2019)
systematic manipulation of the spatial frequency of the visual target revealed more prevalent, and
shorter-latency SLRs towards targets with low spatial frequencies (0.15, 0.3, 0.6 cpd) compared
to high spatial frequencies (1.11, 1.6, 2.22 cpd). As expected, the latency of online corrections is
also shorter in response to the low spatial frequency targets (Veerman et al., 2008; Marino et al.,
2012; Kozak et al., 2019). Together, these results provide important information on the nature of
the first wave of muscle recruitment, which evidently carries information about the location, but
not detailed information about the identity of the stimulus. These findings lend support for the
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hypothesized role of the superior colliculus (SC) in generating the SLR, given the broad
literature documenting modulation of neural activation in the SC by varying the luminance
contrast, spatial frequency, and motion of the visual stimulus, in the same way that the SLR is
modulated (Schneider & Kastner, 2005; Li & Basso, 2008; Marino et al., 2012; Chen et al.,
2018).
The SC is a phylogenetically well-preserved oculomotor structure in the midbrain that
integrates multi-modal incoming sensory information from the environment and translates it into
efferent orienting motor commands (Corneil et al. 2002, 2008; Rezvani & Corneil, 2008; Song et
al. 2011, 2015; Gandhi & Katnani, 2016; Cooper & McPeek, 2021). The superficial layer of the
SC receives visual information directly from the retina, and indirectly through the retinogeniculo-cortical pathway; and the intermediate and deep layers facilitate the transformation
from visual input to motor commands (Lane et al., 1973; Grantyn and Grantyn 1982; Werner,
1993; Werner et al., 1997; May, 2006). The SC is the head of the tecto-reticulospinal tract, and
projects through the premotor bundle to the reticular formation. Although predominately known
for its role in generating saccadic eye movements, the SC is integral to orienting the head and
limbs towards salient stimuli and has more recently been found to play a broader role in guiding
behaviour. Werner (1993) discovered a subset of neurons in the deep layers of the SC and the
underlying reticular formation of non-human primates that produce action potentials before, and
during reaching arm movements. This activity was temporally correlated to EMG activity in
proximal limb muscles (Werner et al., 1997; Stuphorn et al., 2000). Importantly, this subset of
neurons did not display saccade-related activity, suggesting a functionally distinct population of
SC neurons associated with limb control. Furthermore, functional magnetic imaging (fMRI)
investigation has found reach-related activity in the contralateral SC to the reaching arm in
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humans (Himmelbach et al., 2013), and electrical microsimulation of the SC and reticular
formation elicits arm movements in non-human primates (Philip and Hoffman, 2014). Together,
these findings demonstrate the role of the SC in coordinating stimulus-driven recruitment of
proximal limb muscles via the tecto-reticulospinal tract and make the SC a likely candidate for
the neural substrate of the SLR.
Additional evidence supporting the role of the SC in SLR generation and modulation
comes from Gu et al. (2018), who investigated the frame of reference of the directional tuning of
the SLR by dissociating the starting position of the hand and gaze relative to the stimulus. It was
found that the SLR is generated in a hand-centric manner, meaning that it drives the arm in the
direction of the stimulus relative to where the hand is positioned, not relative to where the eyes
are fixated. This suggests that visual information about the location of the target is integrated
with sensory information about the position of the hand to dictate the directionality of the motor
burst. Importantly, a subset of neurons in the SC are also activated in a hand-centric, rather than
a gaze-centric, manor in response to visual stimuli (Stuphorn et al., 2000; Song et al., 2011).
Comparably to the SLR, a portion of SC reach-related neural activity in the SC is directionally
tuned to the location of the target, regardless of the direction of the reach. These findings suggest
that this subset of SC neurons generate stimulus-driven motor signals related to the general
location of the automated reaching goal, rather than control of the reach kinematics, which aligns
with the nature of the SLR (Cooper and McPeek, 2021).
An extensive body of literature describes the SC as the site of integration for converging
signal pathways from the cortex and midbrain, which serve to modulate fast visuomotor
responses. One of the most critical modulatory pathways converging on the SC comes from the
substantia nigra pars reticulata (SNr), the output region of the basal ganglia (BG) (Hikosaka et
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al., 2000; Shires et al., 2010; Watanabe & Munoz, 2011; Coe & Munoz, 2017). Much of what we
know about SC modulation via the BG comes from studies of saccadic eye movements, which
can be used to predict the modulatory mechanisms governing the SLR. The SNr provides
continuous tonic inhibition to both the contralateral, and ipsilateral SC via GABAergic output
(Karabelas & Moschovakis, 1985; Behan et al., 1987; Bickford & Hall, 1992; Jiang et al., 2003;
Liu & Basso, 2008). Transient cessation of these inhibitory post-synaptic potentials disinhibits
saccade-generating neurons, and initiates eye movements. Therefore, the BG modulate saccadic
eye movements by adjusting the inhibitory activity imposed on the SC by the SNr. The DS,
comprised of the caudate nucleus (CN) and putamen, accomplishes this by balancing activity
through the direct and indirect pathways, which are generally known to facilitate and inhibit
motor output respectively (described in detail above).
Regulation of the direct and indirect pathways by the DS is critical for response selection
between automatic and volitional oculomotor commands (Parent & Hazrati, 1995; Smith et al.,
1998; Hikosaka et al., 2000; Nakano et al., 2000; Sato et al., 2000a; Kita, 2007). Watanabe and
Munoz (2009) reported three distinct populations of neurons in the CN that are differentially
activated during the pro/anti-saccade task in non-human primates using single neuron recordings:
neurons 1) active before contralateral pro-saccades and ipsilateral anti-saccades (i.e., always
tuned to the location of the stimulus), 2) active before contralateral volitional saccades regardless
of stimulus direction, and 3) active before ipsilateral anti-saccades (Watanabe & Munoz 2009).
Pro/Anti-saccade trials and left/right presenting stimuli were randomly interleaved throughout
the study. Preceding the execution of an anti-saccade, the first and second populations are
proposed to stimulate the direct pathway to the SNr, thereby promoting automatic stimulusdriven, and volitional saccades respectively. When an anti-saccade instructional cue is given
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before target onset, the preparatory activity in the neurons driving volitional saccades is more
active than when a pro-saccade cue is given, to compensate for the competing stimulus-driven
response. This heightened preparatory activity is not seen preceding trials when subjects make a
faulty saccade toward the stimulus. To resolve the conflict between these two signals driving
saccades in opposite directions, the third population is proposed to activate the indirect pathway
and selectively inhibit the stimulus-driven response, thus preventing initiation of an incorrect
saccade towards the stimulus in favour of the voluntary command. Therefore, Watanabe and
Munoz suggest that successful performance of an anti-saccade requires sufficient activation of
the voluntary response via the direct pathway, and complementary inhibition of the automatic
response via the indirect pathway to overcome the stimulus-driven signal. Consequently,
stimulus-driven saccade responses are less reliant on the BG than controlled/volitional eye
movements.
These results can help explain the replicated finding that volitional, memory-guided
saccades are impaired, but automated stimulus-driven saccades are intact and often disinhibited
in PD (Fischer & Weber, 1993; Briand et al., 1999; Chan et al., 2005; Cameron et al., 2010). The
underlying mechanism of this phenomenon is not yet clear, however a prominent hypothesis is
that because of delayed reaction times of voluntary movement and hypoactivity of the dorsal
lateral prefrontal cortex (dlPFC), a critical structure in the preparation of voluntary movement,
the delayed initiation of the anti-saccade allows more time for the SC to be triggered by visual
signals from the stimulus (Dagher & Nagano-Saito, 2007; Cameron et al., 2009; Cameron et al.,
2010). Therefore, in PD patients the voluntary signal might not be strong or fast enough to elicit
a voluntary command before the stimulus-driven response is triggered by visual input from the
retina, though more research in this area is needed. Another possible explanation is that an intact

18

compensatory cerebellar pathway to the intermediate layers of the colliculus allows visually
guided responses to bypass the dysfunctional BG (Roldan & Reinoso-Suarez, 1981; Glickstein &
Stein, 1991; Westby et al., 1994).
Given the important modulatory role of the BG on the SC, and the resulting impairments
on tests of oculomotor control, it is expected that BG dysfunction will disrupt contextual
modulation of the SLR. Although there is ample evidence for the role of the SC in the generation
of the SLR, the neural substrate responsible for attenuating the magnitude of this response
according to task instructions remains unclear. By studying the SLR in patients with PD, we aim
to investigate the role of the BG in this process.

1.3 The Present Study
The purpose of this study is to address the existing gap in knowledge regarding the effect
of the pathology of Parkinson’s disease (PD) on the modulation of the fast visuomotor pathway
for reaching. Although there is growing evidence of the preservation of rapid visuomotor
responses, including the stimulus-locked response (SLR), in patients with PD, it remains unclear
whether the ability to modulate the SLR is equally intact. This study aims to build on the recent
finding from our lab that the SLR is preserved in patients with PD by assessing the effect of
contextual control of this response. Although Kozak found no differences between PD patients
and healthy controls in the ability to modulate the magnitude of the SLR on Anti-reach compared
to Pro-reach trials, participants had > 1500 ms to consolidate the instructional cue of each trial
before target onset. Given that this finding is unexpected in the context of the current literature,
this task might have allowed participants too much time to prepare to reach away from the
stimulus to detect differences in SLR modulation between groups. Therefore, the current study
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aims to challenge the participants by only providing the Anti-reach or Pro-reach instructional cue
either 500 ms or 1000 ms before the target emerges. This will reduce the time available for preemptive, top-down inhibition on the fast visuomotor pathway to modulate SLR magnitude in
favour of the appropriate goal-driven response (Coe & Munoz, 2017). By measuring the SLR
magnitude on upper limb muscles during an anti/pro-reach task with varying instruction times
both off and on dopamine (DA) medication, this study aims to 1) elucidate the effect of DA
deficiency in the BG of PD patients on contextual modulation of the SLR and 2) to determine the
effect of instruction time on SLR modulation in patients with PD.
This study will provide novel insight into the role of the dorsal striatum (DS) on the
modulation of the earliest phase of muscle recruitment in reaching. Recording muscle
activity with EMG allows us to detect changes in muscle activity with greater temporal
resolution than what other studies in PD patients have been able to achieve using measures of
kinematic events alone. Theoretically, different patterns of early muscle recruitment can produce
identical actions, complicating inferences about muscle recruitment from measures of reaction
times or error rates. The use of EMG circumvents the confounds created by the arm’s inertia,
enabling clearer assessment of the command issued to the motor periphery. Importantly, this
design also allows enough temporal precision to dissociate the effects of PD on the modulation
of the fast visuomotor system from the effects of PD on the subsequent muscle recruitment
driving the voluntary response.
We hypothesized that BG function is critical for the contextual control of the SLR, and
that PD patients would demonstrate impaired inhibitory modulation of this response on the
anti/pro-reach task. Specifically, we predicted that while off DA medication, PD patients would
generate SLRs of equal magnitude on Anti-reach trials and Pro-reach trials. This would suggest a
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deficit in the modulation of the SLR, as healthy participants generate smaller SLRs on Antireach trials compared to Pro-reach trials. The difference in magnitude of the SLR on Anti-reach
trials compared to Pro-reach trials can be used as a measure of contextual control. Conversely,
we predicted that while on dopaminergic medication, patients would generate SLRs of
smaller magnitude on Anti-reach trials and demonstrate the same level of inhibitory control as
healthy participants. Furthermore, we expected that the deficit in contextual control in the PD
group would be most apparent on trials with only 500 ms of instruction time compared to trials
with 1000 ms of instruction time, as they are required to integrate the contextual information into
the visuomotor circuitry more quickly, making the task more difficult. Owing to research
restrictions at Western University during the COVID-19 pandemic, we were unable to collect
data from age-matched healthy control participants. Therefore, this thesis will examine the
performance of PD patients on and off their medication to investigate the effect of dorsal
striatum function on SLR modulation. Data collection from control participants will be
completed when it is approved to do so by the university.

Chapter 2
2

Methods

2.1 Participants
All participants were recruited by phone from the Movement Disorders Database at
London Health Sciences Centre. Ten participants who had received a clinical diagnosis
of idiopathic Parkinson’s disease (PD) from a movement disorder neurologist were enrolled in the
study (5 females, 5 males). Restrictions on research at Western University in response to the
COVID-19 pandemic prevented recruitment of the targeted sample size of 20 PD patients and 20
age-matched healthy controls. However, the manipulation of dopamine (DA) medication within
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the participants allows for exploratory investigation into the role of DA in fast visuomotor
response for the purpose of this thesis. A larger sample of PD patients and a healthy control
group will be tested for this study when participant testing at Western University resumes. All
participants were taking previously prescribed dopaminergic medication to manage their PD
symptoms at the time of recruitment and were responsive to their current dose (Levodopa dose
equivalency: M=624.80 mg, SD=403.23). Exclusion criteria included a diagnosis of any
neurological disorder besides PD; a history of alcohol or drug abuse, psychiatric disorders,
dementia, or hallucinations; uncorrected visual deficits including colour blindness; a history of
deep brain stimulation treatment; and injuries or conditions preventing normal movement of the
right arm. Participants were screened over the phone and filled out a Health and Demographics
questionnaire before participating (Appendix A). Participants provided written, informed consent
(Appendix B) at the time of their first session in accordance with the Declaration of Helsinki
(1991), and all procedures were approved by the Health Sciences Research Ethics Board of
Western University (Appendix C). All participants were compensated $15/h for a total of $75.00
for their time spent participating in this study.
Participants completed two identical experimental sessions at the Brain and Mind
Institute at Western University in London, Ontario, a minimum of 24 h apart. One session was
completed in the ON condition, in which participants were instructed to take their regular
medication as prescribed by their neurologist. The other session was completed in the OFF
condition, in which participants were asked to refrain from taking their dopaminergic or DA
agonist medication before the test. Participants stopped taking DA agonists, such as
pramipexole (Mirapex), 16-18 h before the testing session, and stopped taking DA replacement
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medication, such as levodopa-carbidopa (Sinemet), 12-14 h before the testing session. The order
of ON and OFF sessions was counterbalanced across participants to eliminate the risk of
confounding order effects on task performance. The Movement Disorders Society-Unified
Parkinson’s Disease Rating Scale Motor Subscale (MDS-UPDRS III) was employed at both
testing sessions to evaluate PD symptom severity and verify the effectiveness of the
dopaminergic medication manipulation.
2.2 Demographic, Cognitive, and Affective Assessments
At each experimental session participants completed several questionnaires to assess
demographic, cognitive (Table 1), and affective (Table 2) measures to gain insight into the
characteristics of the patient sample and perform comparisons across medication states when
applicable. All cognitive assessments were completed by patients in the ON state. In addition to
the questionnaires described in detail below, participants completed the Epworth Sleepiness Scale
(Appendix D; Johns, 1991), Barratt Impulsiveness Scale (Appendix E; Barratt et al., 1975),
Oxford Happiness Questionnaire (Appendix F; Hills & Argyle, 2002), Questionnaire for
Impulsive-Compulsive Disorders in Parkinson’s Disease (Appendix G; Weintraub et al., 2011),
Verbal and Category Fluency Test (Appendix H), and Sensation Seeking Scale (Appendix I;
Zuckerman et al., 1964). As these were collected for the purpose of comparison between patients
with Parkinson’s disease (PD) and healthy controls, they were not analyzed for this thesis, but
will be used in future analyses.
.
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Table 1 Demographic and clinical information from participants (n=10); N-FOG = New Freezing of
Gait Questionnaire, higher score indicates more severe symptoms; UPDRS = Movement Disorders
Society Unified Parkinson Disease Rating Scale, higher score indicates more severe symptoms; MoCA
= Montreal Cognitive Assessment, higher score indicates better performance; AMNART = American
version of the Nelson Adult Reading Test, higher score indicates higher estimated intelligence

Table 2 Affective questionnaire data (n=10); BDI = Beck Depression Inventory II, higher score indicates
higher incidence of depressive symptoms; BAI = Beck Anxiety Inventory, higher score indicates higher
incidence of anxiety symptoms; SAS = Starkstein Apathy Scale, higher score indicates higher incidence of
apathy
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2.2.1 New Freezing of Gait Questionnaire (N-FOG)
The N-FOG (Appendix J; Nieuwboer et al., 2009) was used to evaluate the severity of
freezing of gait, a symptom of PD associated with disease severity. Freezing of gait episodes are
defined as: “experiencing the feeling that the feet are transiently glued to the floor while trying to
initiate walking, making a turn, or when walking through narrow spaces or crowded
places”. Participants who did not report freezing of gait (n=5) received a score of 0, and those
who did report this symptom (n=5) received a score between 1 and 29, with higher scores
indicating higher frequency and severity of FOG episodes.

2.2.2 Montreal Cognitive Assessment (MoCA) and American Version of the Nelson Adult
Reading Test (AMNART)
Participants completed the MoCA (Appendix K; Nasreddine et al., 2005) and AMNART
(Appendix L; Grober et al., 1991) to assess cognitive ability and premorbid verbal IQ
respectively. The MoCA is a standard test used to screen for cognitive impairment by assessing
short-term memory, attention, verbal fluency, executive functioning, and visuospatial abilities
with a variety of short tasks (e.g., drawing a clock, recalling a list of words, repeating a
sentence). Higher scores indicate higher cognitive functioning, and a cutoff of at least 23/30
points was used as exclusion criteria in accordance with the suggested cutoff for older adults
reported by Carson et al. (2018). The AMNART is a reading test developed to estimate IQ from
the number of words read aloud correctly from a 50-item list, and the participant’s years of
formal education: (118.2-0.89(errors)+0.64(years of education)). A higher score indicates higher
estimated verbal intelligence.

2.2.3 Bond and Ladder Visual Analogue Mood Scale (BL-VAS)
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The BL-VAS was used to measure changes in mood over the period of the session
(Appendix M; Bond & Ladder, 1974). The questionnaire consists of 16 mood scales (horizontal
lines) with opposing feelings at either end (e.g., calm and excited). Participants were instructed
to draw a vertical line through each scale to indicate their current state based on the relative
proximity of the line to each word. Sub scores were calculated for alertness, calmness, and
contentedness. Values in Table 2 are reported as the difference between the BL-VAS score at the
beginning and end of the session on each testing day (negative values indicate a decrease over
time). Given the potential fatiguing effect of dopamine (DA), this measure was used to
ensure that changes in these measures over the course of the session did not affect participants’
performance differently in the ON vs the OFF condition, which is confirmed by the values in
Table 2.

2.2.4 Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI),
and Starkstein Apathy Scale (SAS)
Approximately 20-40% of patients with PD experience depression, anxiety, and apathy.
These affective symptoms were assessed with the BDI-II (Beck et al., 1996), BAI (Beck et al.,
1988) and SAS (Appendix N; Starkstein et al., 1992) at the end of each session. Higher scores
indicate higher self-reported incidence of each trait. BDI-II and BAI scores range from 0-63.
BDI-II scores are interpreted using the following guidelines: minimal depression 0-13, mild
depression 14-19, moderate depression 20-28, severe depression ≥29. The BAI scores are
assessed as follows: minimal anxiety 0-7, mild anxiety 8-15, moderate anxiety 16-25, severe
anxiety ≥26. SAS scores range from 0-42 with a cut-off of ≥14 used to identify those with
apathy.
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2.3 Behavioural Task
Participants performed a behavioural task using a KINARM end-point robot (BKin
Technologies, Ltd.), which allows the user to control a real-time cursor on a screen by generating
planar reaching movements with a manipulandum beneath the screen. The paradigm used in this
study was a modified version of the Emerging Target paradigm described in Kozak (2020). This
task has been successful at reliably eliciting stimulus-locked responses (SLRs) in upper limb
muscles in previous studies (Kozak et al., 2021; Contemori et al., 2021). At the beginning of each
trial, a target appeared at the top of the screen (Figure 2). The target then descended behind
a visual occluder for 1000 ms before emerging in continuing motion below the occluder at either
the right or left outlet. As soon as the target emerged from the occluder, in the Pro-reach trials,
participants used their right arm to quickly reach toward the target, whereas in the Anti-reach
trials, they used their right arm to quickly reach away from the target as quickly as they
could. This instruction was conveyed to participants by the colour of a small fixation square at
the bottom of the occluder, on which participants were asked to fixate while the target was
behind the barrier. In all trials, the fixation square was initially coloured grey, and prior to target
emergence, turned red on Anti-reach trials and green on Pro-reach trials. As a novel extension to
a similar paradigm previously used in the lab, the fixation point changed colour either 500 ms
or 1000 ms before the target emerged. In this way, we could identify differences in the time
required for task instruction to modulate rapid visuomotor responses while patients were off and
on medication. If participants reached in the wrong direction according to task instruction, the
words “Wrong Way” appeared, and if the participant reached in the correct direction the words
“Hit” appeared. Conversely, if no response was detected before the end of the trial, the word
“Missed” appeared on the screen. The task consisted of five blocks of 104 trials. Anti- and Pro-
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reach trials, left-ward and right-ward targets, and trials with 500 ms and 1000 ms of instruction
time, were randomly assorted throughout each block of trials. In total there were 65 trials of each
of the eight different trial types: Anti/Left/500 ms, Anti/Left/1000 ms, Anti/Right/500 ms,
Anti/Right/1000 ms, Pro/Left/500 ms, Pro/Left/1000 ms, Pro/Right/500 ms, Pro/Right/1000 ms.

Figure 2 Schematic of the KINARM screen through time during pro-reach and anti-reach trials of the
Emerging Target paradigm. The participant's hand controls the white curser at the bottom.

2.4 Data Acquisition
The emerging target task was programmed in MATLAB/Simulink (Mathworks, Inc.)
and Dexterit-E (BKin Technologies, Ltd.) for the KINARM end-point robot. During the task, two
single-differential surface electrodes were placed on the right pectoralis major muscle. One was
placed on the sternal head, and one was placed more laterally on the clavicular head. This
muscle was chosen because it is heavily activated during planar cross body reaches, it is easily
accessible on participants, and it reliably expresses stimulus-locked responses (SLRs; Kozak et
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al., 2020; Kozak et al., 2021). Off-line analysis of the signal from the two electrodes was
compared, and the electrode with the best signal-to-noise ratio across both days was selected
for further analysis for each participant. In all cases, whichever recording (e.g., sternal or
clavicular head) chosen on the first day was also chosen on the second day. EMG data were
recorded with the Delsys Inc. Bagnoli-8 system at 1 kHz and amplified by 1000 (Bagnoli-8
System, Delsys Inc., Boston, MA). This system uses a band-pass filter to filter the EMG signal to
between 20 Hz and 450 Hz. Offline, EMG signals were full-wave rectified and smoothed using a
7 point running average filter prior to further analysis. During the task, a small force was applied
to the manipulandum to elicit baseline activity in the muscle of interest (5 N right and 2 N
towards the participant). Because the participant was required to activate his/her muscle to hold
the cursor centrally at the beginning of each trial, right-ward SLRs and reaches were detectable
as a decrease in activity relative to baseline. EMG activity was normalized to baseline activity for
each trial to account for variations in EMG signal across patients and testing days. In addition to
EMG data, the KINARM system recorded position and kinematic data at 1 kHz from highresolution force/torque sensors in the manipulandum. Eye movements were also recorded with
two EOG surface electrodes placed adjacent to each eye, however the high noise-to-signal ratio
of most participants’ data rendered the recordings unusable for analysis of eye movement
reaction times.

2.5 Data Analysis
2.5.1 Data Exclusion
Trial-by-trial data were examined via a customized MATLAB Graphical User
Interface to exclude obviously atypical trials. Trials were excluded for the following reasons: a)
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no reach was made, indicating a lack of attempt to follow task instruction, or b) the arm was
obviously in motion prior to target appearance. Sequences where the subject initially moved in
the incorrect direction before moving in the correct direction were retained. Trials were
excluded from analysis if the reaction time was shorter than 130 ms or longer than 500 ms based
on the time at which the participant reached 5% of the peak velocity, to eliminate a) movement
resulting from anticipatory activity, b) tremor in the starting position, or c) aberrantly delayed
reactions due to inattention. Together, these criteria screened out 12.9% of trials (OFF: 13.1%;
ON: 12.8%), with 12.8% of trials excluded based on reaction time cutoffs.

2.5.2 Planned Statistical Analysis
To investigate the effects of Instruction Time (500 ms vs 1000 ms), Trial Type (Antireach vs Pro-reach), and Medication State (OFF vs ON) on our selected dependent variables
described below, linear mixed models were used to quantify main effects and interactions. Linear
mixed models were chosen over repeated-measures analysis of variance (ANOVA) because of
their ability to account for missing data (e.g., if a participant expressed an SLR in one but not
another condition). Unlike ANOVAs, linear mixed models do not use list-wise deletion in the
case of missing data points which allowed us to maximize the power and reduce the bias of our
analysis. The Satterthwaite method was applied to estimate degrees of freedom and generate pvalues for the mixed model analyses. Instruction Time, Trial Type, and Medication State were
specified as fixed effects, and participant ID was specified as a random effect in the linear mixed
models. Post-hoc orthogonal contrasts with the Bonferroni correction method for multiple
comparisons were used to investigate significant interactions between predictor variables. Data
processing was done in MATLAB (R2014b), and statistical analyses were performed in JASP.
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2.5.3 Behavioural and Kinematic Analysis
Several behavioural parameters were assessed. Reaction time (ms) was calculated as the
time at which the participant’s arm reached 5% of the peak velocity following target onset. Only
correct trials were included in reaction time calculations. For error rate calculations, any trial in
which a participant’s initial arm movement went in the incorrect direction in reference to the task
instruction was considered an error. Error rates (%) are represented as a percentage of total trials
of that type in the respective medication state. There are roughly 130 trials of each of the four
trial types in each medication state: 1) Anti-reaches with 500 ms of instruction, 2) Anti-reaches
with 1000 ms of instruction, 3) Pro-reaches with 500 ms of instruction, 4) Pro-reaches with 1000
ms of instruction.
The peak velocity (m/s) for each trial was calculated from the first segment of the
reaching movement to eliminate confounds created by including corrective, or secondary
movements in this analysis. Time to peak velocity (ms) was used as a construct of acceleration
and was calculated as the time from the reaction time, or the point at which the participant’s arm
reached 5% of its peak velocity, to the point at which the arm reached peak velocity on each
trial. Movement duration (ms) was quantified as the time from the reaction time to the point at
which the velocity of the arm fell below 5% of the peak velocity.

2.5.4 EMG Analysis
The stimulus-locked response (SLR) is the first burst of muscle activity that drives the
arm towards a visual stimulus within 80-120 ms after stimulus onset. Figure 3 illustrates the
EMG activity of a representative participant in the OFF condition. The SLR is the visible change
in activity that consistently appears around 100 ms. The presence of the SLR was identified
using a time series receiver operating characteristic (ROC) curve analysis. ROC curves quantify
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the probability that an ideal observer could discriminate between leftward and rightward stimuli
conditions from EMG activity alone. ROC curves were constructed for averaged EMG activity at
each ms from 50 ms before, to 300 ms after target onset. An area under the curve (AUC) of 0.5
represents chance-level discrimination, and an AUC value of 1 represents perfect discrimination
(Green & Swets, 1966). SLR onset was identified as the time point at which the AUC value
surpassed a discrimination threshold of .65 for a minimum of 5 of the subsequent 8 ms. Figure 4
shows averaged EMG activity from a single representative participant in the OFF condition, and
the corresponding plot of time series ROC values used to detect SLR onset. If the ROC curve did
not pass this threshold between 80 ms and 120 ms from target onset, an SLR was not detected,
and that participant was not included in the latency analysis for the respective trial type
(Contemori et al., 2020). The discrimination time was calculated for each trial type and used to
analyze SLR prevalence and magnitude. Trials in which the participant went in the correct
direction or went ≤ 50% of the distance of their average reach in the wrong were included in the
analysis of SLR prevalence and latency.
For analysis of SLR magnitude, SLR onset was determined by finding the discrimination
time for all averaged pro-reach trials in each medication state (OFF and ON) for each participant.
This discrimination time was used for the analysis of SLR magnitude on all trial types (Anti- and
Pro-reach) to ensure that EMG activity was being analyzed in a consistent time window to allow
for comparison between Anti- and Pro-reach trials. SLR magnitude was calculated as the integral
of the difference curve between the averaged EMG activity on leftward and rightward reaches
for each trial type, from the time of SLR onset to 30 ms after SLR onset.
The SLR modulation index was calculated as a measure of the suppression of the SLR on
Anti-reach trials relative to the SLR on Pro-reach trials: (Pro-Anti)/(Pro+Anti). This index
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ranged from -1 to 1. An index of 1 would indicate complete suppression of the SLR on Antireach trials, an index of 0 would indicate SLRs of equal magnitude on Anti-reach and Pro-reach
trials, and an index of –1 would indicate complete suppression of the SLR on Pro-reach trials.
To investigate the magnitude of the SLR as a function of the magnitude of movementrelated activity (%), it was analyzed as a percentage of the magnitude of the EMG burst
preceding movement onset for the respective trial type. The movement-related motor burst was
identified as the peak in the difference curve of averaged EMG activity between leftward and
rightward movements in the period between 100 ms and 0 ms before movement onset.
The magnitude of this motor burst was calculated as the integral of the difference curve from 15
ms before, to 15 ms after the peak.
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(µV)

Figure 3 EMG colour plots of a single representative participant on pro- and anti-reach trials
with left and right ward appearing stimuli. White squares indicate reaction time of the correct
reach for each trial. The SLR appears between 80 ms and 120 ms from target onset, which can
be seen in the black rectangles.
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Chapter 3
3

Results
The aim of our analyses was to investigate the effects of Instruction Time, Trial Type,

and Medication State on a number of behavioural, kinematic, and EMG measures. A pairedsample t-test (t(8) =-4.28, p=.001) revealed that MDS-UPDRS scores were significantly higher
in the OFF condition compared to the ON condition (OFF: M=43.3, SE=4.21, SD=11.9; ON:
M=32.2, SE=4.18, SD=11.8), indicating that the manipulation of dopaminergic medication had
the expected beneficial effects on the primary motor symptoms of Parkinson’s disease (PD). We
expected this would also be evident in the error rate and kinematic features of voluntary reaches
on the behavioral task, but would have no effect on the magnitude or latency of the stimuluslocked response (SLR). We also predicted that Medication State would have a significant effect
on SLR modulation, such that there would be less modulation of the SLR on Anti-reach trials in
the OFF condition. This section will outline the results of behavioural and kinematic analyses,
followed by the results of the EMG data, focusing on the SLR. Although the kinematic features
of participants’ reaches consistently trended in the expected direction between medication states,
the study was likely underpowered to detect significant differences. There were no reliable trends
in the effect of dopamine (DA) on SLR generation, as seen in the consistency of SLR prevalence,
latency, and magnitude between medication states. Surprisingly, despite the significant effect of
Instruction Time on SLR modulation, there was no evidence of an effect of Medication State on
SLR modulation, even with only 500 ms of instruction time when the task was most challenging.
Though there were no consistent trends of medication effects on the magnitude of the SLR, there
was a trend toward the expected positive effect of dopaminergic medication on the magnitude of
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movement-related activity, suggesting a differential effect of DA on different stages of muscle
recruitment.

3.1 Behavioural and Kinematic Analysis
3.1.1 Reach Reaction Time
Reach reaction time was measured as the time from target onset to the time at which the
arm reached 5% of its peak velocity. The linear mixed model analysis revealed a significant main
effect of Instruction Time on reach reaction time [F(1,10)=101, p<.001]. Participants had
significantly longer reaction times with 500 ms of instruction time relative to 1000 ms of
instruction time (Figure 5a; 500 ms: M=259, SE=7.21, SD=45.6; 1000 ms: M=230, SE=5.82,
SD=36.8). This indicates that when participants had less time to consolidate the instructional cue,
they took longer to initiate their response, suggesting the manipulation of instruction time was
successful at making the task more cognitively taxing for participants. There was also a
significant main effect of Trial Type [F(1,9)=74.6, p<.001]. Participants had significantly
prolonged reaction times on Anti-reach trials than on Pro-reach trials, which is expected on this
task based on previous results from our lab, as participants must overcome the initial impulse to
reach towards the target before moving the arm in the opposite direction on Anti-reach trials
(Anti-reach: M=274, SE=36.8, SD=16.6; Pro-reach: M=215, SE=4.36, SD=27.6). There was a
significant interaction between Instruction Time and Trial Type [F(1,45)=11.8, p=.001], which
indicated that participants had significantly longer reaction times with 500 ms of instruction than
with 1000 ms of instruction on both Anti-reach (500 ms: M=291, SE=8.31, SD=36.6; 1000 ms:
M=257, SE=6.54, SD=28.5; p<.001) and Pro-reach trials (500 ms: M=227, SE=6.38, SD=27.8;
1000 ms: M=204, SE=5.15, SD=22.5; p<.001), and this difference was greater on Anti-reach
trials. There was no significant main effect of Medication State on reaction time [F(1,9)=.041,
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p=.842], and the mean reaction time was very similar off and on medication (OFF: M=245,
SE=7.03, SD=44.5; ON: M=244, SE=6.87, SD=4304). There were no other significant
interactions between predictor variables (p>.05).
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3.1.2 Error Rate
Error rate was measured as the percentage of trials in which the participant made a
directional error relative to the instructional cue (i.e., the participant reached towards the target
on Anti-reach trials or away from the target on Pro-reach trials). Participants had more difficulty
with the task on trials with shorter instructional cues, especially on Anti-reach trials (Figure 5b).
There was a significant main effect of Instruction Time on error rate [F(1,14)=39.8, p<.001], as
participants made significantly more errors with 500 ms of instruction relative to 1000 ms of
instruction (500 ms: M=20.1, SE=2.22, SD=14.0; M=10.6, SE=1.52, SD=9.61). There was also a
significant main effect of Trial Type [F(1,10)=109, p<.001]. Participants made more errors on
Anti-reach trials than on Pro-reach trials (Anti-reach: M=24.7, SE=1.78, SD=11.3; Pro-reach:
M=6.01, SE=.867, SD=5.48). There was a significant interaction between Instruction Time and
Trial Type [F(1,50)=.547, p=.023]. Post-hoc orthogonal contrasts with the Bonferroni correction
method revealed that participants made significantly more errors with only 500 ms of instruction
compared to 1000 ms of instruction on both Anti-reach trials (500 ms: M=31.0, SE=2.51,
SD=10.9; 1000 ms: M=18.4, SE=1.73, SD=7.52; p=.002) and Pro-reach trials (500 ms: M=9.15,
SE=1.34, SD=5.85; 1000 ms: M=2.87, SE=.596, SD=2.60; p<.001). There was no significant
main effect of Medication State [F<1] on error rate, although participants made slightly more
errors while off medication than while on medication (OFF: M=15.8, SE=2.09, SD=13.2; ON:
M=14.8, SE=2.00, SD=12.7). Figure 5b illustrates that the expected trend towards improved
performance while on medication is most evident with only 500 ms of instruction, when the task
is more challenging. This suggests that when participants had less time to consolidate the
instructional cue before reacting they demonstrated a slight deficit in performance when off their
medication, but this did not reach significance. There were no other significant interactions
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between predictor variables (p>.05). These results highlight the clear effect of the duration of the
instructional cue on the participants’ performance. In accordance with the reaction time results,
these results indicate that the decrease in instruction time from 1000 ms to 500 ms was
successful at making this task more challenging. Figure 5b illustrates the amplification of the
negative effect of shorter instruction time on Anti-reach trials, in which the participants must
reach in the opposite direction of the target by quickly consolidating the instruction to suppress
the urge to reach towards it.

3.1.3 Peak Velocity
The peak velocity of the reaching arm was calculated to assess the speed at which the
participants reached towards/away from the target. There was a significant main effect of
Instruction Time [F(1,9)=7.40, p=.024], indicating participants reached a higher peak velocity
with 500 ms of instruction time compared to 1000 ms of instruction time (Figure 5c; 500 ms:
M=.510, SE=.002, SD=.147; 1000 ms: M=.501, SE=.002, SD=.140). This result suggests that
participants moved more quickly with less time to consolidate the instructional information
before target onset. This could be explained by the delayed reaction times with 500 ms of
instruction compared to 1000 ms of instructions: participants must move their arm faster to reach
the target the later they initiate the reach to compensate for lost time, because the target is in
constant downward and outward motion from the time of emergence. There was no significant
main effect of Trial Type [F(1,9)=4.75, p=.057], although participants reached lower peak
velocities on Anti-reach trials than on Pro-reach trials, and this effect approached significance
(Anti-reach: M=.527, SE=.002, SD=.130; Pro-reach: M=.479, SE=.003, SD=.156). This trend
suggests that participants tend to make slower movements when instructed to reach away from
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the target than when they are instructed to make a more automated response towards it. There
was no significant main effect of Medication State on peak velocity [F(1,9)=4.87, p=.055],
however participants reached a lower average peak velocity while off medication relative to on
medication, and this effect approached significance (OFF: M =.499, SE=.002, SD=.139; ON:
M=.512, SE=.002, SD=.148). Although not statistically significant, this trend suggests that
dopaminergic medication had the expected positive effect on the maximum speed of participants’
movements. There were no significant interactions between any of the predictor variables
(p>.05).

3.1.4 Time to Peak Velocity
The time required for the participants’ arm to reach its peak velocity was used as a
construct of reach acceleration. There was no significant main effect of Trial Type on the time
taken to reach peak velocity [F(1,9)=4.38, p=.066], although participants reached peak velocity
later on Anti-reach trials than on Pro-reach trials (Anti-reach: M=286, SE=1.48, SD=84.7; Proreach: M=275, SE=1.15, SD=73.6). Medication State did not have a significant main effect on
the time required to reach peak velocity [F(1,9)=1.29, p=.286], although, in-line with the results
of the analysis of peak velocity, participants reached peak velocity slightly later in the OFF state
than in the ON state (OFF: M=282, SE=1.27, SD=76.8; ON: M=278, SE=1.32, SD=80.8). This
indicates that not only do participants tend to reach lower speeds while off dopaminergic
medication, they also accelerate less quickly in their movement and, in turn, reach their
maximum velocity later. There was a significant interaction between Medication State and Trial
Type [F(1,36)=4.96, p=.032]. Post hoc orthogonal contrasts with the Bonferroni correction
method indicated that participants reached peak velocity significantly later on Anti-reach trials
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than on Pro-reach trials in the ON condition (Anti-reach: M=289, SE=16.6, SD=72.4; Pro-reach:
M=273, SE=13.5, SD=58.8; p=.022), but there was no significant difference between Anti- and
Pro-reach trials in the OFF condition, although the data followed a similar trend (Anti-reach:
M=291, SE=15.5, SD=67.9; Pro-reach: M=281, SE=13.3, SD=57.9; p=.122). Figure 5 shows that
this interaction is driven by the short time required to reach peak velocity on Pro-reach trials
while on dopaminergic medication. There was no significant main effect of Instruction Time on
time to peak velocity [F(1,9)=1.92, p=.197], however participants reached peak velocity slightly
later with 500 ms of instruction time relative to 1000 ms of instruction time (Figure 5d; 500 ms:
M=282, SE=1.31, SD=79.4; 1000 ms: M=278, SE=1.28, SD=78.3). Together with the results of
the peak velocity analysis, this indicates that with shorter instruction time participants reach a
higher maximum velocity, but take slightly longer to reach that velocity, compared to trials with
longer instruction time. There were no other significant interactions between predictor variables
(p>.05).

3.1.5 Movement Duration
Movement duration was calculated as the time from the reaction time to the time at which
the velocity of the reaching arm fell below 5% of its peak velocity. There was no significant
main effect of Instruction Time on movement duration [F<1], and the mean movement duration
was very similar for trials with 500 ms of instruction time and 1000 ms of instruction time (500
ms: M=563, SE=2.00, SD=122; 1000 ms: M=565, SE=2.02, SD=124). There was also no
significant main effect of Trial Type on movement duration [F(1,9)=3.08, p=.106], although
participants made shorter movements on Anti-reach trials than on Pro-reach trials, indicating that
participants take longer to complete their reach when instructed to reach away from the target,
than when they are instructed to reach towards it (Figure 5e; Anti-reach: M=552, SE=2.15,
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SD=124; Pro-reach: M=574, SE=1.86, SD=121). There was also no significant main effect of
Medication State on movement duration [F(1,9)=3.29, p=.103], although participants’ movement
durations were higher while on medication than off medication (OFF: M=571, SE=1.98,
SD=121; ON: M=558, SE=2.03, SD=125). This trend is consistent with the findings of the
previous kinematic analyses, as participants tend to accelerate less quickly, reach lower
velocities, and take more time to complete their reaches in the OFF condition. There were no
significant interactions between any of the predictor variables (p>.05).
In summary, the behavioural and kinematic data displayed the expected trends of
dopaminergic medication effects on movement. Participants made faster and shorter reaches
while on medication and made fewer errors while on medication on the trials with only 500 ms
of instruction. The data are congruent with our prediction that having a shorter instruction period
before target emergence would make the task more difficult. Participants made significantly
more errors and had longer reaction times with only 500 ms of instruction compared to 1000 ms.
Trial type had the expected effect on task performance and reach kinematics, as Anti-reaches
were more difficult and took longer to perform than Pro-reaches. The following section will
discuss the effects of Instruction Time, Trial Type, and Medication State on the SLR, which
interestingly, differ from the effects on voluntary movement.

3.2 EMG Analysis
3.2.1 SLR Prevalence and Latency
The stimulus-locked response (SLR) detection analysis was done on the data from four
different trial types performed in both the OFF and ON state for each participant, for a total of 80
observations (8 conditions x 10 participants). An SLR was detected in 84% of these cases
(Figure 6a, 6b). All participants displayed an SLR on at least three of the eight conditions: OFF-
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Anti-500 ms: 90%; OFF-Anti-1000 ms: 50%; OFF-Pro-500 ms: 90%; OFF-Pro-1000 ms: 100%;
ON-Anti-500 ms: 80%; ON-Anti-1000 ms: 80%; ON-Pro-500 ms: 80%; ON-Pro-1000 ms:
100%. A Chi-square test indicated that the prevalence of an SLR did not differ between OFF and
ON conditions (X2(1)=.092, p=.762).

A

B

C

OFF 1000ms

Figure 6 A) SLR prevalence expressed as the percentage of participants expressing an SLR on each
trial type in the ON condition B) SLR prevalence expressed as the percentage of participants
expressing an SLR on each trial type in the ON condition C) Mean (SEM) SLR latency relative to
target onset on pro- and anti-reaches. *p<.05, **p<.001

Figure 4 shows averaged EMG activity from a single representative participant in the
OFF condition (4a), and the corresponding plot of time series receiver operating characteristic
(ROC) curve values used to detect SLR onset (4b). SLR latency was calculated as the time
between target emergence and SLR onset (Figure 6c). There was no significant main effect of
Instruction Time on SLR latency [F(1,7)=.402, p=.545], and mean SLR latency was relatively
consistent with 500 ms of instruction and 1000 ms of instruction (500 ms: M=100, SE=1.51,
SD=8.81; 1000 ms: M=99.0, SE=1.53, SD=8.81). There was no significant main effect of Trial
Type on SLR latency [F(1,7)=3.20, p=.117], and again, participants had very similar SLR
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latencies in the Anti-reach and Pro-reach conditions (Anti-reach: M=101, SE=1.80, SD=9.85;
Pro-reach: M=98.5, SE=1.27, SD=7.71). There was no significant main effect of Medication
State on the latency of the SLR [F(1,8)=4.39, p=.069], and mean SLR latency was similar while
off medication and on medication (OFF: M=101, SE=1.74, SD=9.97; ON: M=98.6, SE=1.27,
SD=7.41l). There were no significant interactions between any of the predictor variables (p>.05).
Figure 6c demonstrates the consistency of SLR latency across conditions, which is to be
expected given the time-locked nature of the SLR to stimulus onset, regardless of varying
reaction times.

3.2.2 SLR Magnitude
The most critical result for testing our hypothesis was the analysis of SLR magnitude. If
dopamine (DA) input to the dorsal striatum (DS) is involved in the modulation of the SLR, then
an Instruction Time x Trial Type x Medication State interaction would be expected. However,
we did not see this in the results, as the magnitude of the SLR in the Anti- relative to the Proreach condition was not influenced by Medication State, regardless of Instruction Time. There
was a significant main effect of Instruction Time on SLR magnitude [F(1,9)=5.43, p=.044], as
the mean SLR magnitude was significantly smaller with 500 ms of instruction than with 1000 ms
of instruction (Figure 7a; 500 ms: M=21.8, SE=2.25, SD=13.9; 1000 ms: M=27.6, SE=3.92,
SD=24.2). There was also a significant main effect of Trial Type [F(1,9)=70.2 p<.001], as SLRs
were significantly smaller on Anti-reach trials than on Pro-reach trials (Anti-reach: M=10.2,
SE=1.19, SD=7.36; Pro-reach: M=39.2, SE=2.85, SD=17.5). There was a significant interaction
between Instruction Time and Trial Type [F(1,33)=41.1, p<.001], which revealed that SLR
magnitude was significantly greater with 500 ms of instruction time than with 1000 ms of
instruction time on Anti-reach trials (500 ms: M=12.0, SE=1.77, SD=7.51; 1000 ms: M=8.34,
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SE=1.63, SD=6.90; p<.001), but smaller with 500 ms of instruction time than with 1000 ms of
instruction time on Pro-reach trials (500 ms: M=31.5, SE=2.79, SD=11.8; 1000 ms: M=46.8,
SE=4.53, SD=19.2; p<.001). This result highlights the relationship between Instruction Time and
the influence of the task instruction on the magnitude of the SLR. Figure 7a shows that when
participants have more time to consolidate the cue, the SLR can be more significantly dampened
on Anti-reaches. Surprisingly, there was no significant main effect of Medication State on the
magnitude of the SLR [F(1,9)=1.33, p=.280]. Mean SLR magnitude was slightly smaller while
off medication than while on medication, however unlike the effect of Medication State on
movement-related EMG activity, there was no consistent trend towards decreased activity in the
OFF condition during the SLR period (OFF: M=23.8, SE=3.14 SD=18.9; ON: M=25.5, SE=3.29,
SD=20.8). Medication State did not interact with the other predictor variables (p>.05).
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3.2.3 SLR to Movement-related Activity Comparison
The purpose of this analysis was to determine the magnitude of the SLR in each
condition relative the movement-related activity in the respective condition. There was a
significant main effect of trial type, as the magnitude of the SLR was a significantly smaller
proportion of movement-related activity on Anti-reach trials compared to Pro-reach trials (Figure
7b; Anti-reach: M=14.2%, SE=2.10, SD=12.9; Pro-reach: M=48.8%, SE=3.50, SD=21.7). There
was no significant main effect of Instruction Time [F(1,9)=3.13, p=.111]. Participants had a
slightly smaller SLR relative to movement-related EMG activity with only 500 ms of instruction,
compared to 1000 ms of instruction (500 ms: M=28.6%, SE=3.10, SD=19.0; 1000 ms: M=34.4%,
SE=4.80, SD=29.6; p<.001). There was a significant interaction between Instruction Time and
Trial Type, which indicated that the SLR magnitude was a greater proportion of movementrelated EMG activity with 500 ms than with 1000 ms of instruction on Anti-reach trials (500 ms:
M=17.0%, SE=3.23, SD=13.9; 1000 ms: M=11.4%, SE=2.74, SD=11.6; p<.001), but a smaller
proportion with 500 ms than with 1000 ms on Pro-reach trials (500 ms: M=40.2%, SE=3.83,
SD=16.3; 1000 ms: M=57.3%, SE=5.53, SD=23.5; p<.001). These findings highlight the
surprisingly large magnitude of the SLR in comparison to movement-related activity, particularly
when participants are instructed to reach towards the target and have more time to process the
instructional cue. There was no main effect of Medication State on the SLR magnitude expressed
as a proportion of movement-related activity [F<1]. The mean percentage was consistent in the
OFF and ON states (OFF: M=31.8%, SE=4.00 SD=2.37; ON: M=31.2%, SE=3, SD=4.10,
SD=2.61). There were no other significant interactions between predictors (p>.05).
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3.2.4 SLR Modulation
SLR modulation was quantified with an index that represents the amount that the SLR
was dampened on Anti-reach trials relative to Pro-reach trials. An index of 1 indicated complete
suppression of the SLR on Anti-reach trials, and an index of 0 indicated SLRs of equal
magnitude were generated on Anti- and Pro-reach trials. Higher values indicated greater
modulatory control of the SLR. In accordance with the SLR magnitude results, there was a
significant main effect of Instruction Time on SLR modulation [F(1,13)=17.5, p=.001], but not a
significant main effect of Medication State [F(1,10)=1.78, p=.212]. Participants had a lower
modulation index with 500 ms of instruction time than with 1000 ms of instruction time (Figure
7c; 500 ms: M=.471, SE=.050, SD=.220; 1000 ms: M=.732, SE=.039, SD=.170). The mean
modulation index was slightly higher while off medication relative to on medication (OFF:
M=.652, SE=.057, SD=.242; ON: M=.556, SE=.050, SD=.225), however this difference was not
significant. There was not a significant interaction between Medication State and Instruction
Time (p>.05), indicating that regardless of instruction time, there was no difference between
SLR modulation in OFF and ON state.

3.2.5 Movement-related Activity
The effects of Instruction Time, Trial Type, and Medication State on movement-related
EMG activity were assessed to investigate whether there are differential effects of these variables
on voluntary muscle recruitment immediately preceding movement onset compared to the effects
of these variables on the SLR. There was no main effect of Instruction Time [F<1], and
participants had very similarly-sized bursts of EMG activity preceding movement with 500 ms of
instruction and 1000 ms of instruction (Figure 7d; 500 ms: M=82.3, SE=4.95, SD=31.3; 1000 ms:
M=83.4, SE=5.00, SD=31.6). There was also no significant main effect on Trial Type [F<1], and
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the magnitude of movement-related EMG activity was similar preceding Anti-reaches and Proreaches (Anti-reach: M=81.5, SE=5.05, SD=31.9; Pro-reach: M=84.3, SE=4.90, SD=31.0). There
was also no significant main effect of Medication State on the magnitude of EMG activity
immediately preceding movement onset [F(1,9)=2.54, p=.145], however participants had lower
movement-related activity in the OFF condition than in the ON condition (OFF: M=76.6,
SE=3.66, SD=23.1; ON: M=89.1, SE=5.84, SD=37.0). Although not significant, Figure 7d
illustrates the clear tendency of movement-related EMG activity to be smaller in the OFF
condition relative to the ON condition, on both Anti- and Pro-reach trials. This consistent trend
suggests an influence of dopaminergic medication on muscle activity immediately preceding
movement initiation, which was not observed in the results of SLR magnitude. There were no
significant interactions between predictor variables (p>.05).
In summary, Medication State had no influence on the SLR latency, prevalence, or
magnitude. The unexpected lack of Instruction Time x Trial Type x Medication State interaction
effect on SLR magnitude indicated that Medication State did not differentially affect SLR
magnitude in the Anti-reach condition. This translates to no effect of Medication State on the
modulation of the SLR, which does not support the hypothesis that DA input to the dorsal
striatum (DS) is critical for the contextual control of the SLR. Instruction Time significantly
influenced the magnitude and modulation of the SLR, but even with only 500 ms of instruction
time participants suppressed the SLR on Anti-reach trials to the same degree in the OFF and ON
conditions. Interestingly, there was consistently stronger EMG activity during the movementrelated burst in the ON condition, suggesting that although the voluntary muscle recruitment was
affected by DA, the initial stimulus-driven wave of muscle recruitment comes from a separate,
DA independent system.
3.3 Relationship with Clinical Measures
Although the sample size was small, we conducted exploratory analysis to see if any
clinical measures were correlated with a number of behavioural and EMG measures.
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Multiple linear regression models indicated that disease duration, Freezing of Gait (FOG) score,
and MDS-UPDRS score in the OFF condition did not significantly predict stimulus-locked
response (SLR) magnitude (F(3,5) =3.18, p=.122, R2=.450), SLR modulation (F(3,5)
=5.10, p=.060, R2=.606), reaction time (F(3,6) =2.54, p=.152, R2=.340), peak velocity (F(3,6)
=.036, p=.990, R2=-.474) time to peak velocity (F(3,6) =3.58, p=.086, R2=.463), error rate
(F(3,6) =3.42, p=.094, R2=.631), or movement-related EMG activity (F(3,5)
=2.76, p=.152, R2=.397).

Chapter 4
4

Discussion

4.1 Summary of Results
To assess the modulation of the stimulus locked-response (SLR) in patients with
Parkinson’s disease (PD), it was essential that participants understood the task and were able to
respond appropriately to the contextual cue. At the same time, one of the primary goals of this
study was to investigate the effect of a shorter instructional time on SLR modulation, following
the surprising result from previous work in the lab that SLR modulation was unaffected in PD
patients, with the assumption that a more challenging task might be necessary to precipitate
group differences. The error rate and reaction time results indicate that participants were able to
understand the task and performed very well in both the OFF and ON condition. It is evident
from the error rate and reaction time data that the manipulation of instruction time from 1000 to
500 ms was successful at making the task more challenging, without preventing the participants
from performing a reasonable number of correct trials.
Although not statistically significant, the trends of the medication effect on reach
kinematics suggest bradykinetic movement in this sample of PD patients. Participants had
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consistently lower peak velocities, longer times to peak velocity, and consequently longer
movement durations in the OFF state compared to the ON state. This trend is congruent with the
assumption that voluntary movement was affected by basal ganglia (BG) dysfunction in these
patients, such that intact visuomotor responses would indicate a differential effect of the disease
on these two types of movement. This assumption is also confirmed by the statistically
significant increase in scores on the Movement Disorders Society Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) in the OFF condition relative to the ON condition. Together, these
results also validate the manipulation of dopaminergic medication state. They confirm that the
ON sessions were conducted at the appropriate time in participants’ daily medication schedule to
avoid the effects of the medication wearing off during the sessions, and that withholding
medication for 16-18 hours before the OFF sessions was sufficient to see the expected effect of
dopamine (DA) deficiency on motor symptoms.
Despite the successful manipulation of task difficulty by varying the instruction time, and
the validated manipulation of dopaminergic medication between ON and OFF sessions, there
was no effect of DA depletion on the SLR. The prevalence, latency, and magnitude of the SLR
was equivalent in the OFF and ON conditions, supporting the hypothesis that DA pathways in
the BG are not critical for the generation of fast visuomotor responses. PD patients generated
SLRs on the vast majority of trial conditions, with 100% of patients expressing SLRs on Proreaches with 1000 ms of instruction time in both the OFF and ON conditions. Additionally, it is
worth noting that the mean SLR magnitude on Pro-reaches with 1000 ms of instruction time both
off and on medication was almost 60% of the magnitude of movement-related EMG activity,
indicating a high degree of output from the fast visuomotor pathway in PD patients, regardless of
DA deficiency in the BG. Interestingly, while the magnitude of the SLR was nearly identical in
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the OFF and ON conditions, the magnitude of movement-related activity was consistently
smaller in the OFF condition. Collectively with the finding of decreased velocity and
acceleration in the OFF condition, this further supports the notion of different pathways
converging on motor neurons, with the fast visuomotor pathway carrying less susceptibility to
DA than the slower volitional pathway.
The most surprising result of this study was the lack of an Instruction Time x Trial Type
x Medication State interaction on SLR magnitude, and consequently the lack of an effect of
Medication State on SLR modulation. Though the generation of rapid visuomotor responses was
expected to be intact in PD, it was hypothesized that the dorsal striatum (DS) of the BG plays an
essential role in suppressing the SLR when the stimulus location is incongruent with the
movement goal (i.e., Anti-reach trials). However, the null result suggests that this process is not
affected by DA deficiency. PD patients generated significantly smaller SLRs on Anti-reach trials
than on Pro-reach trials in all conditions, which is consistent with the effect of Trial Type on the
SLR reported by studies in younger, healthy participants. Importantly, the modulation index, or
the ratio of the SLR on Anti-reach to Pro-reach trials, was not significantly different in the OFF
and ON conditions. Furthermore, the index was slightly higher in the OFF state suggesting that
the inability to detect a deficit in the OFF state was not simply attributable to a lack of statistical
power. Despite increased task difficulty on trials with 500 ms of instruction time as seen by the
significant decrease in the modulation index compared to trials with 1000 ms, there was still no
benefit of DA medication on SLR modulation.

4.2 The SLR is Intact in PD
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The finding of a robustly intact stimulus-locked response (SLR), independent of
dopamine (DA) medication state, is congruent with the current literature reporting a seemingly
paradoxical, spared fast visuomotor system in patients with Parkinson’s disease (PD). Firstly,
these results are consistent with recently collected data by our lab (Kozak) in PD patients. Kozak
found no differences between PD patients and healthy controls in SLR prevalence, latency, or
magnitude, and no effect of Medication State, suggesting that the visuomotor pathway
responsible for generating the SLR is not impaired by DA deficiency in the dorsal striatum (DS).
Further, our results are consistent with the findings of Merritt et al., (2017) that online
corrections to stimulus-guided reach trajectories can be performed by PD patients with the same
latency and accuracy as healthy controls. These online corrections are thought to be initiated by
the same neural circuitry as the SLR, given that SLRs are associated with shorter latency online
corrections when assessed in the same task (Kozak et al., 2019). Therefore, it was expected that
the SLR would be similarly spared by PD.
The high incidence and magnitude of the SLR in PD patients is also consistent with
results of oculomotor studies. The effect of PD on saccadic eye movements differs between
externally cued reflexive saccades, and non-cued volitional saccades (i.e. memory guided
saccades). In the presence of a visual stimulus, PD patients make more short-latency express
saccades than healthy controls (Briand et al., 1999; Chan et al., 2005; Terao et al., 2011; Lu et
al., 2019). This result suggests that fast visuomotor responses are not only intact in PD patients
but may even be upregulated. This is in stark contrast to the significant delay in volitional eye
movements in the absence of a visual stimulus seen in PD patients. Given that the SLR is also a
stimulus-driven, short latency response, likely generated by the tecto-reticulospinal tract (Gu et
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al., 2016; Gu et al., 2018; Kozak et al., 2019; Kozak et al., 2021), it is unsurprising that our
results correspond with reports of express saccades in PD patients.
Our SLR results support the current hypothesis that fast visuomotor responses remain
intact in PD, despite over-inhibition of volitional movement, suggesting a separate motor
pathway is involved. In PD, GABAergic output from the internal segment of the globus pallidus
(GPi) and substantia nigra pars reticulata (SNr) to the intermediate layers of the SC is enhanced
by upregulation of the indirect, and downregulation of the direct pathway of the basal ganglia
(BG), caused by DA depletion in the DS (See Chapter 1). The resulting over-inhibition of
downstream motor areas is responsible for the primary motor symptoms of PD: reduced and
slowed volitional movement. The results of this study exhibit the expected trends of reduced
reach velocity and acceleration, and increased movement duration in the OFF condition. It was
expected that reaction times would be prolonged in the OFF condition, however previous studies
have also shown no effect of DA on reaction times on simple reaching tasks, even when reaction
times were significantly longer than healthy controls and DA medication improved MDSUPDRS scores (Jahanshahi et al., 1992; Michely et al., 2012). Therefore, this task may not have
been complex enough to see the effect of DA therapy on reaction times, but there may still be an
apparent deficit when we compare this data to healthy controls.
Although the exact mechanisms of spared visuomotor responses in PD are unknown,
inferences can be made from studies of the neural substrates of oculomotor control via
converging projections to the superior colliculus (SC), which is presumed to be the common
origin of both saccadic eye movements and the SLR. The fronto-BG-SC pathway is essential for
both initiating and inhibiting visuomotor commands sent from the SC to the downstream
reticular formation, and subsequently to motor neurons involved in orienting the eyes, head, and
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limbs (Figure 8). SC neurons in the caudal and rostral regions initiate and suppress reflexive eye
movements towards salient stimuli respectively, and the relative activity in each of these regions
dictate the behavioral outcome (Munoz & Wurtz, 1992). Modulatory projections originating in
cortical regions including the dorsal lateral prefrontal cortex (dlPFC), frontal eye field (FEF),
supplementary eye field (SEF), and posterior parietal cortex (PPC) reach SC neurons directly,
and indirectly via the inhibitory BG (Mountcastle et al., 1975; Lynch et al., 1977; Stanton et al.,
1989; Pare & Wurtz, 1997; Munoz, 2002; Brown et al., 2006; Dash et al., 2020). Generally, the
intermediate layer of the SC receives predominantly inhibitory input directly from the BG and
dlPFC, and excitatory input from the FEF, PPC, and cerebellum (Gaymard et al., 2003). The
dlPFC and FEF also exert inhibitory effects on the SC via projections to the caudate nucleus
(CN) and subthalamic nucleus (STN) in the BG, which in turn increases GABAergic output of
the GPi/SNr.
Motor output from the intermediate and deep layers of the SC is involved in both
reflexive (stimulus driven) movements, and voluntary (internally driven) movements, and
distinctions in the way in which these responses are modulated are important for understanding
the preservation of the SLR in PD. Specifically, the dlPFC, FEF, and SEF are predominantly
involved in volitional saccades, such as memory-guided or un-cued saccades, whereas the PPC is
predominantly involved in reflexive, cued saccades (Pierrot‐Deseilligny et al., 1987; Shibutani et
al., 1984; Pierrot‐Deseilligny et al., 1991; O’Driscoll et al., 1995; Schall et al., 1995; Sweeney et
al., 1996; Thier & Anderson, 1996; Andersen et al., 1997; Grosbras et al., 1999; Gaymard et al.,
2003; Parton et al., 2007). Dash and colleagues (2020) reported that inactivation of the FEF
reduced the peak velocity of express (short-latency, stimulus-driven) saccades, but did not
abolish them, suggesting that the FEF is involved, but not essential in express visuomotor
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responses. Terao et al. (2016) assessed internally driven and stimulus driven saccades in patients
with a variety of cortical lesions and found FEF lesions were associated with prolonged latency
of internally driven, but not stimulus driven saccades. In contrast, lesions in the PPC were
associated with prolonged latency of stimulus driven saccades. dlPFC lesions were associated
with impaired ability to suppress automatic, stimulus-driven saccades when instructed to make a
voluntary saccade in the opposite direction (anti-saccade), which supports the notion that the
direct inhibitory projection from the dlPFC to the SC is a critical pathway for the suppression of
competing reflexive responses in favour of initiating voluntary movement (Guitton et al., 1985;
Munoz & Everling, 2004; Pierrot-Deseilligny et al., 2004; Hodgson et al., 2007).
In PD patients, aberrant activity in the BG and dlPFC is associated with deficits in
executing internally driven actions and suppressing unwanted stimulus driven responses.
Jahanshahi et al. (2010) reported that internally guided movements were associated with greater
activation of the dlPFC compared to externally guided movements, and that the dlPFC was
hypoactive in patients with PD compared to controls. The hypoactivity of the dlPFC was
correlated with hyperactivation of the GPi, which has inhibitory output to the dlPFC.
Consequently, the inhibitory projection from the dlPFC to the SC which is activated during
internally guided movements, in downregulated in PD. The hypoactive dlPFC is hypothesized to
play a role in the inability of PD patients to suppress reflexive visuomotor responses during
voluntary movement, as seen on numerous oculomotor tasks (Briand et al., 1999; Hood et al.,
2007; Chan et al., 2005; Cameron et al., 2009). According to Brown et al., the default response
of SC motor neurons is to orient the head, eyes, and limbs towards salient stimuli according to
direct visual input to the superficial layer, and sufficient inhibition is required to perform an
action that is not congruent with stimulus-driven reactions. Therefore, hypoactive dlPFC
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projections selectively impair volitional movements, leaving visually guided responses, like the
SLR, intact and possibly upregulated.
In addition to reduced activity in the dlPFC in PD, Jahanshahi et al. (2010) also reported
increased cerebellar activation. This was also reported by Yu et al. (2007), who interpreted this
finding as a compensatory mechanism in response to increased inhibitory output from the BG.
Interestingly, the BOLD activation of the ipsilateral cerebellum and the contralateral putamen
were negatively correlated in PD patients performing a thumb pressing task. Additional evidence
for this hypothesis comes from Wu et al. (2009; 2010), who found that recruitment of the
cerebello-thalamo-cortical loop was positively correlated with MDS-UPDRS scores, whereas
recruitment of the striato-thalamo-cortical loop was negatively correlated with MDS-UPDRS
scores. It is still unclear whether this phenomenon is indeed compensatory, or a pathological
result of uninhibited cerebellar activity (Wu et al., 2013). Critically for the interpretation of the
results of this study, the cerebellum has excitatory projections to the SC, and the downstream
reticular formation (Noda et al., 1990; Stein & Glickstein, 1992; Fuchs et al., 1993; Guillaume &
Pelisson, 2001; Robinson & Fuchs, 2001; Thier & Mock, 2006; Buzunov et al., 2013).
Inactivation of the caudal fastigial nucleus (cFN) of the cerebellum in non-human primates
significantly impairs saccades towards a target (Goffart et al., 2004). Further, gaze shifts evoked
by stimulation of the deep layers of the SC were slower and smaller when the cFN was
inactivated. Therefore, although the increased inhibitory output from the BG to the SC
theoretically inhibits both internally guided and stimulus guided movement, the hypoactivity of
the dlPFC during volitional movement and the hyperactivity of the cerebellum might make it
difficult for the volitional motor command to be executed before the reflexive response is
triggered in the SC, resulting in a response bias towards automatic actions in PD patients. Given
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the stimulus-driven and automatic nature of the SLR, the results of our study are congruent with
a preserved fast visuomotor network.

muscles

Figure 8 Schematic of the circuitry involved in modulating oculomotor responses, adapted from Coe & Munoz
(2017).
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4.3 SLR Modulation is Intact in PD Patients, but Sensitive to Instruction Time
In light of the literature discussed above, it was hypothesized that the modulation of the
stimulus-locked response (SLR) would be impaired in Parkinson’s disease (PD), and that this
deficit would be remedied by dopamine (DA) medication. However, the results of our study do
not support this hypothesis and suggest that the system modulating the SLR is independent of
DA loops in the basal ganglia (BG). This result conflicts with the well-documented deficit in PD
patients in suppressing automatic responses to external stimuli, in favour of initiating a voluntary
response that is incongruent with the stimulus. In the PD literature, the anti-saccade task is the
most analogous behavioural task to the anti/pro-reach task used to study the SLR. PD patients
show profound deficits in the ability to inhibit a saccade towards a suddenly appearing target
(Briand et al., 1999; Chan et al., 2005; Terao et al., 2011; Terao et al., 2013; Lu et al., 2019).
Therefore, the finding that the SLR is significantly dampened on Anti-reach trials compared to
Pro-reach trials was unexpected. Further, PD patients have a response bias towards automated
movements. Compared to healthy controls, they have more difficulty switching from an
automatic motion to a volitional motion but perform better than healthy controls when switching
from a volitional to an automated motion (Cameron et al., 2010). The literature consistently
indicates a role of the dorsal striatum (DS) in the modulation of automatic visuomotor responses
(Praamstra et al., 2001; Obeso et al., 2008; Gauggel et al., 2004; Cools, 2006; Hood et al., 2007;
Ali et al., 2010; Beste et al., 2010; Liu et al., 2010; Zandbelt et al., 2013), however this was not
supported by our SLR modulation results.
This surprising result has two possible explanations. First, the SLR could be modulated
by a different mechanism than other express oculomotor responses, which are well-known to be
upregulated and disinhibited in PD patients. The exact neural circuitry of the generation and
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modulation of the SLR is not as clear as the neural circuitry involved in generating eye
movements, and so it is possible that the assumed role of the BG-superior colliculus (SC)
pathway in SLR modulation is incorrect. However, the strong evidence for the role of the SC in
generating the SLR, and the recruitment of the striatum for response inhibition on a wide range
of cognitive and motor tasks render this explanation unlikely (Brown & Marsden, 1988; Henik et
al., 1993; Dujardin et al., 1999; Cools, 2006; Ali et al., 2010; Liu et al., 2010; Zandbelt et al.,
2013; Jahanshahi et al., 2015).
The alternative, and more likely, explanation is that there is a deficit in the contextual
control of the SLR in PD patients, especially with shorter instruction times, that is not affected
by DA medication. The effect of DA medication on deficits on the anti-saccade task in PD
patients is inconsistent across studies, and deficits are frequently reported in patients both on and
off their prescribed medication (Briand et al., 1999; Hood et al., 2007; Chan et al., 2005;
Cameron et al., 2009). Therefore, the lack of a medication effect on the modulation of the SLR
must be interpreted with caution. Though the SLR modulation index is relatively high with 1000
ms of instruction (~0.70), indicating an influence of task instruction on the magnitude of
stimulus-driven muscle recruitment, the index is significantly reduced with only 500 ms of
instruction time. It could be that the modulation of the fast visuomotor pathway is not abolished
in PD, but rather requires more time for the contextual information to influence visuomotor
responses. This is compatible with a large group of experiments involving simple reaction time
and cued choice reaction time tasks, which showed that PD patients can process, and benefit
from pre-stimulus cues, but they require longer cues than healthy controls to gain the same
amount of “benefit” (i.e. the same reduction in reaction time relative to uncued trials) (Talland,
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1963; Wiesendanger et al., 1969; Girotti et al., 1986; Stelmach et al., 1986; Mayeux et al., 1987;
Lichter et al., 1988; Reid et al., 1989).
The results of SLR magnitude show that instruction time has significant effects on both
Anti- and Pro-reach trials suggesting that the instruction time is used to either prime or suppress
the SC accordingly. With longer instruction times, the SLR is significantly smaller on Anti-reach
trials and greater on Pro-reach trials. Collectively with the prolonged reaction time, and higher
error rates on trials with only 500 ms of instruction time, this supports the hypothesis that the
bias towards stimulus driven responses in PD might be because of a deficit to initiate the
voluntary response and suppress the automatic response before the automatic response is
initiated by excitatory visual input into the SC. Testing this hypothesis will require a control
group, which will elucidate whether there is a modulation deficit in PD compared to healthy
controls, or whether SLR modulation is indeed independent from the pathological effects of PD.
The results of this study so far indicate that the design is well-equipped to make informative
comparisons of the effect of instruction time on SLR modulation in PD versus HC, given the
difficulty of trials with only 500 ms of instruction for patients. I predict that the difference in
modulation between trials with 500 ms and 1000 ms of instruction will be greater in the PD
group compared to HC.

4.4 Limitations and Future Directions
The greatest limitation of this study was the lack of control data as a consequence of the
COVID-19 pandemic. This study was initially designed with the intention of comparing
stimulus-locked response (SLR) modulation in patients with Parkinson’s disease (PD) to healthy
controls both off and on dopamine (DA) medication, which would allow us to investigate the
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effect of the pathology of PD without relying on the effects of DA medication. The current data
allowed us to address two of our three aims which were to 1) investigate the effect of instruction
time on SLR modulation in PD, 2) investigate the effect of DA medication on SLR modulation
in PD, and 3) investigate the effect of PD on SLR modulation. Control data are expected to be
collected in Fall 2021, which will enable us to address the third aim of this study.
Additionally, the small sample size limited the statistical power of this study. The
inability to detect statistically significant differences between the OFF and ON conditions for
any of the variables analyzed limit our ability to make robust conclusions about the effects of DA
on the SLR. However, the direction of the trends in the data suggest a differential effect of DA
medication on EMG activity at different times during the motor response. Specifically, though
the magnitude of EMG activity during the SLR window was nearly identical in the OFF and ON
conditions, it was consistently smaller in the OFF condition preceding movement onset. This
result warrants further investigation to decipher the involvement of DA in the initial wave of
muscle recruitment compared to the volitional movement. It is also possible that the reaching
motion required in this paradigm is too simple to elicit significant differences between
medication states, as the effect of DA medication is known to be more prominent on more
complex motor tasks (Benecke et al., 1987; Hanna-Pladdy & Heilman, 2010). Therefore, the null
result of the effect of DA on the SLR could be supported by testing the same group of patients on
a more complex voluntary motor task which produces measurable effects of DA as a comparison
to the SLR.
Finally, this paradigm was designed with a moving target in light of the finding from
Kozak et al., (2020) that a moving target is superior to a stationary target at eliciting robust
SLRs. However, this creates a confounding effect of reaction time on the distance the participant

62

must reach to hit the target, as the distance of the target from the initial hand position varies with
the time from target emergence. Although this should not influence the SLR, this has
implications for measures of reach amplitude, peak velocity, time to peak velocity, and
movement duration. This confound creates foreseeable problems when this data is compared to
healthy controls, as PD patients are expected to have significantly longer reach reaction times.
More recently, Contemori and colleagues (2020) reported that flashed stationary targets can in
fact elicit stronger magnitude SLRs than moving targets, as long as the target emergence is
temporally predictable. Future studies of the SLR in PD patients should take this into
consideration when designing the paradigm, as using a flashed stationary target will standardize
the movement goal regardless of any changes in reaction time.

4.5 Conclusions
In conclusion, this study provides strong evidence that rapid visuomotor responses
remain intact in patients with Parkinson’s disease (PD), as demonstrated by the high prevalence
and magnitude of stimulus-locked responses (SLRs) on the Emerging Target task. The speed of
reaches and magnitude of movement related EMG activity was slightly lower in the OFF
condition, consistent with known EMG abnormalities associated with bradykinesia and
hypokinesia. In contrast, we found no statistically reliable differences in the magnitude of the
SLR in the OFF and ON conditions, suggesting a differential effect of dopamine (DA) on
different stages of muscle recruitment. PD patients demonstrated modulation of the fast
visuomotor pathway by eliciting smaller SLRs on Anti-reach trials, however the modulation
index was significantly lower with less instruction time preceding target emergence. Though
there was no effect of DA medication on the modulation index, control data from healthy
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participants is needed to confirm whether the effect of instruction time on SLR modulation is
affected by dorsal striatum dysfunction in PD.
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Appendices
Appendix A: Health and Demographic Questionnaire
For administrator’s use only
Score:

Date (dd/mm/yy):
Subject #:
Group:

Session #:
Time:

Health and Demographic Questionnaire
Please print and fill out this form as accurately as possible and bring it with you to your first
appointment session. If you are attending your appointment with another participant, please
ensure you both have your own personal copies filled out.

1. Basic Demographic Information
Date of Birth: _____________________________
Weight: ________

Age: _______
Height: _______

Handedness: _____________
First language: __________________

Other languages: ___________________________

Level of Education and total years (e.g. 4 years high school, 4 years university, etc.)
______________________________________________________________________________
Occupation: ______________________________

2. Health-Related Information
A. Smoking History (please circle):

Never Smoker

Ex-Smoker

Current Smoker

If current smoker, indicate how many years and how many cig/day: _______________________
If ex-smoker, indicate year that you quit; how many years smoking; how many cig/day:
______________________________________________________________________________
B. Alcohol History
Average number of drinks per week: _____________
Has there ever been heavy alcohol consumption? (please circle)

Yes

No

If yes, when, for how long, and estimate your weekly alcohol consumption during that time:
______________________________________________________________________________
C. Other Drug History
Have you ever taken street drugs or other drugs that were not prescribed by a physician (please
circle)?

Yes

No

If yes, when, what drugs, how frequently and over what period of time?
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For administrator’s use only
Score:

Date (dd/mm/yy):
Subject #:
Group:

Session #:
Time:

______________________________________________________________________________
D. Eye Glasses (only if applicable)
What is the prescription of your eye glasses? ______________
Without the aid of glasses are you able to see near objects well (please circle)?

Yes

No

Without the aid of glasses are you able to see far objects well (please circle)?

Yes

No

E. Obsessive-compulsive disorder (OCD; only if applicable)
What year were you diagnosed with OCD? _________________
Are you currently taking medication to treat your OCD? _________________
If yes, what medication? _________________

F. Parkinson’s Disease (PD; only if applicable)
What year were you diagnosed with Parkinson’s disease? _________________
Which side of the body is more affected? _________________

3. Previous Medical Problems
Have you had any major health problems or do you have any chronic, ongoing medical
conditions such as high blood pressure, high cholesterol, diabetes, thyroid problems, multiple
sclerosis or epilepsy? Have you had any strokes, heart attacks/ heart surgeries, significant head
trauma, or cancer? If you've had cancer, what kind and what treatments did you receive (e.g.
chemotherapy)? Have you ever had more than one seizure? Answer in the space below.
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For administrator’s use only
Score:

Date (dd/mm/yy):
Subject #:
Group:

Session #:
Time:

4. Family Medical Problems
Is there anyone in your family with a neurological or serious psychiatric illness such as PD,
Huntington's, epilepsy, strokes at a young age (< 50 for men and < 60 for women)? Is there
anyone who had trouble walking or with balance, needing a wheelchair or a walker at a young
age? Any family members with dementia (such as Alzheimer's), schizophrenia, bipolar/manic
depression, or severe depression or anxiety requiring hospitalization or close follow up by a
psychiatrist? Answer in the space below.
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For administrator’s use only
Score:

Date (dd/mm/yy):
Subject #:
Group:

Session #:
Time:

5. Current Medication
Please list any medications you are currently taking, what they are treating for specifically, and
the prescribed dosage.
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LETTER OF INFORMATION AND CONSENT FORM
In this consent document, “you” always refers to the study participant. If you are a substitute
decision maker (SDM) (i.e. someone who makes the decision of participation on behalf of a
participant), please remember that “you” refers to the study patient. If an SDM is needed for
this study, you will be asked to review and sign this consent form on behalf of the participant.
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During testing, you might perform tests on a computer that are aimed at testing basic aspects
of thinking, memory, or problem solving while you are in a magnetic resonance imaging (MRI)
machine. With MRI, we are able to measure blood flow non-invasively in various parts of your
brain as a marker of brain activity while you perform specific thinking functions. We will also
collect images of your brain in the MRI to measure different brain structures.
Patients with Parkinson’s disease
If you are a patient with Parkinson’s disease, you will be tested twice, once while you are taking
your Parkinson’s medication and once after you have abstained from taking your Parkinson’s
medication for at least 12 hours on two separate days.
Healthy control participants or patients with neurological (e.g. stroke, epilepsy, multiple
sclerosis, multiple systems atrophy, progressive supranuclear palsy, cortico-basal-ganglionic
degeneration, Lewy body dementia, ataxia, Huntington’s disease, Alzheimer’s disease), as well
as sleep disorders (e.g. rapid eye movement sleep behavioural disorder or RBD, restless leg disorder and,
obstructive sleep apnea), or psychiatric disorder (e.g. obsessive-compulsive disorder) other than
Parkinson’s disease
If you are a non-patient volunteer or a patient with a neurological or psychiatric disorder other
than Parkinson’s disease, you might perform the tasks once or twice. In all testing sessions, you
will take all of your regularly prescribed medications. In some studies, you might also take
dopaminergic therapy or a placebo (i.e., cornstarch) in one session or across two sessions.
Patients with addiction (e.g. alcohol, opioids, marijuana)
You will be asked to abstain from all illicit substances as well as alcohol for a minimum of 48
hours prior to testing. Upon arrival on your testing date, you will complete an Orawell Oral
Fluid (Saliva) Drug Test and an Alco-Screen Oral Fluid (Saliva) Alcohol Test to confirm
compliance with these instructions. In all testing sessions, you will take all of your regularly
prescribed medications. In some studies, you might also take dopaminergic therapy or a
placebo (i.e., cornstarch) in one session or across two sessions.
Healthy control participants studied while taking dopaminergic therapy
For non-patient volunteers, in some experiments you will perform tasks once while taking a
dose of Levocarb or Pramipexole, common medications that are used to treat Parkinson’s
disease, and once while taking an inactive or placebo substance (i.e., cornstarch). The order in
which you receive these substances will be randomly determined across participants. You will
not be informed of the substance that you are given in either testing session and the
experimenter will also be blind to which substance you are given on a particular day. This is
done to reduce any effects of expectation that might be induced by knowing that you are
receiving active treatment. Levocarb contains 100 mg of levodopa (L-3,4dihydroxyphenylalanine) and 25 mg of carbidopa. Levodopa is transformed in the brain into
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dopamine whereas pramipexole mimics dopamine. Dopamine is a neurotransmitter produced
naturally in the brain that is involved in regulating movement and some aspects of thinking and
memory. Carbidopa is a substance that does not cross into the brain but is given to stop the
levodopa from being converted to dopamine before it reaches the brain. Carbidopa reduces
side effects that can occur due to dopamine being produced in the body rather than in the
brain, such as nausea or lowering of blood pressure.
Experiments involving propranolol or atenolol
You might be asked to perform some tasks once while taking a dose of propranolol or atenolol,
and once while taking an inactive or placebo substance (i.e., cornstarch). The order in which
you receive these substances will be randomly determined across participants. You will not be
informed of the substance that you are given in either testing session and the experimenter will
also be blind to which substance you are given on a particular day. This is done to reduce any
effects of expectation that might be induced by knowing that you are receiving active
treatment. Propranolol and atenolol are beta blockers. Beta blockers compete with the same
receptors as adrenaline, slowing the sympathetic nervous system to lower heart rate and blood
pressure.
Experiments involving polysomnographic sleep recordings
You might be asked to undergo polysomnographic sleep recordings during either a 3-h daytime
nap or 8-h overnight session. Polysomnography (PSG) is a non-invasive technique that uses
surface electrodes applied to the scalp and face to measure brain activity during different
sleep-wake cycles.
Experiments involving robotic arm manipulation
We will ask you to perform a motor learning task. This will take approximately 40 minutes. You
will be asked to grasp the handle of one or two robot arms, and point to visual targets displayed
on a virtual-reality display. You will be asked to point to targets one after another. Depending
on the phase of the experiment, the robot may be programmed to apply small forces (a few
grams) to your hand during movement. The robot will measure the movement of the handle
(e.g., when movement starts, how fast it is, how curved the trajectory of movement is as you
move to the targets) as an index of motor learning. Throughout the experiment, your muscle
activity will be measured with surface electromyography (EMG) by small, non-invasive
electrodes placed on top of the skin with adhesive tape. These electrodes will be placed on the
upper chest, just below the collarbone. If you have chest hair, the areas where surface
recording will take place might need to be shaved in order to collect good quality data. You are
welcome to remove it yourself before arriving to the study, or we can provide razors and
shaving cream before we attach the electrodes.
Experiments involving electroencephalography
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You might be asked to undergo electroencephalography (EEG) recordings during either the
experimental session. EEG is a non-invasive technique that uses surface electrodes applied to
the scalp and face to measure brain activity during rest or during performance of various
cognitive tasks.
Experiments involving audiometric assessment
You may be asked to listen to sounds through headphones and report when you detect the
sound and when you can no longer hear the sound. This part is expected to take no longer than
12 minutes.
Experiments involving beat/rhythm discrimination
You may be asked to complete auditory tasks involving discrimination of auditory sequences,
and/or tapping during or after listening to auditory sequences. For these tasks, auditory
sequences will be presented via headphones at a comfortable intensity level. Tapping will be
performed on a computer keyboard or external device (e.g., a drum pad) capable of recording
tapping information.
Experiments involving affective processing
You might be asked to view pictures and/or sounds that portray either neural content (e.g.,
chairs, glasses) or negatively valenced content, some of which is graphic or disturbing in nature
(e.g., guns, threat/attack, body mutilation), or a series of faces. Your psychophysiological
responses to these stimuli will be monitored at all times during the task using
electromyography (EMG), galvanic skin response (GSR), electrocardiography (ECG), heart rate,
blood pressure, and respiration.
Experiments involving virtual reality
You might be asked to interact in real-world situations using a virtual reality head set. During
the test, your movements will be tracked using cameras. The virtual reality head set creates a
virtual environment that you can see and interact with.
Experiments involving driving simulation
You may be asked to perform driving tasks using a driving simulator. During the test you will be
sitting in a cockpit designed to replicate a driver’s seat and surrounded by large screens. Tests
will involve performing driving tasks (i.e. navigation, turning, etc…).
Experiments involving social processing
You might be asked to view a series of faces and make judgments about them (e.g., emotion,
age), and/or listen to a variety of jokes while evaluating how funny they were. Throughout
these activities, your facial expression activity will be continuously recorded with
electromyography (EMG).
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Benefits
Your participation in this study is of no direct benefit to you.
Risks
If you require treatment for any injuries or illness directly related to procedures implemented
during the study, or if you suffer side effects while on study medication, you should contact
your study doctor as soon as possible. The necessary medical care will be provided to you at no
additional cost to you. You do not waive any legal rights by signing the consent form.
Participants performing computerized tasks
There are no known physical risks associated with performing computerized tasks. You may find
some of the tasks dull or tiring.
Experiments involving functional magnetic resonance imaging
The Food & Drug Administration (USA) has indicated that for clinical diagnosis an ‘insignificant’
risk is associated with human MRI exposure at the intensities used in this project. Current
Canadian guidelines follow the USA guidelines. Although very rare, injury and deaths have
occurred in MRI units from unsecured metal objects being drawn at high speeds into the
magnet or from internal body metal fragments of which the subject was unaware or had not
informed MRI staff. To minimize this latter possibility it is essential that you complete a
screening questionnaire. Other remote but potential risks involve tissue burns and temporary
hearing loss from the loud noise inside the magnet. The latter can be avoided with ear
headphone protection that also allows continuous communication between the subject and
staff during the study.
This MRI machine uses a strong magnet and radio waves to make images of the body interior.
You will be asked to lie on a long narrow couch for an hour while the machine gathers data.
During this time you will be exposed to magnetic fields and radio waves. You will not feel
either. You will, however, hear repetitive tapping noises that arise from the magnets that
surround you. You will be provided with earplugs or headphones that you will be required to
wear to minimize the sound and protect your hearing. The space within the large magnet in
which you lie is somewhat confined, although we have taken many steps to relieve the
“claustrophobic" feeling. There are no known significant risks with this procedure at this time
because the radio waves and magnetic fields, at the strengths used, are thought to be without
harm. The exception is if you have a cardiac pacemaker, or a metallic clip in your body (e.g.,
an aneurysm clip in your brain), have severe heart disease, body piercings, tattoos containing
metallic ink or slow release pharmaceutical skin patches.
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There is a possibility that you will experience a localized twitching sensation due to the
magnetic field changes during the scan. This is not unexpected and should not be painful.
However, you can stop the exam at anytime. The magnetism and radio waves do not cause
harmful effects at the levels used in the MRI machine. However, because the MR scanner uses
a very strong magnet that will attract metal, all metallic objects must be removed from your
person before you approach the scanner. In addition, watches and credit cards should also be
removed as these could be damaged (these items will be watched for you).
For experiments involving electrophysiological recording (e.g, EMG) inside of the MRI: while
rare, incidents of tissue burning have been reported due to the recording electrodes and cables
heating up inside of the magnet. However, this risk is largely eliminated when proper
equipment and procedures are used. The surface electrodes and cables we use have been
specially designed for use within the MRI and there have been no known burn incidents
reported with this particular equipment. Furthermore, you will also be separated from the
cables by an insulating barrier, and your skin will be prepared according to recommended
safety procedures prior to electrode placement.
Patients with Parkinson’s disease
For Parkinson’s patients who are tested off of their Parkinson’s medications, you likely will
experience an increase in your Parkinson’s symptoms. If you do not return to your usual level
of function after resuming your medication at the conclusion of the testing session, you are
invited to contact Dr. MacDonald to discuss your concerns as well as medication strategies for
getting back to your usual self.
Participants taking dopaminergic therapy
If you are a non-patient volunteer taking levodopa or pramipexole, there is a potential risk of
developing side effects following drug administration. More serious side effects reported are
based on chronic use of these medications in patients, and are not expected to develop in this
study given the single, low-dose of drug administered. Less serious side effects are largely
peripheral effects (e.g., nausea) and should be minimized through co-administration of
Carbidopa. Any side effects that do occur are temporary and should quickly subside. In the
unlikely situation that your symptoms persist, you are invited to contact the experimenter to
discuss your concerns.
Less serious side effects include: mild nausea, dry mouth, loss of appetite; heartburn, diarrhea,
constipation; headache, dizziness, drowsiness, blurred vision; sneezing, stuffy nose, cough,
other cold symptoms; sleep problems (insomnia), strange dreams, muscle pain,
numbness/tingly feelings, skin rash/itching. More serious side effects include: severe allergic
reactions; restless muscle movements in your eyes, tongue, jaw, or neck; worsening of tremors
(uncontrolled shaking); high fever, stiff muscles, sweating, fast or uneven heartbeats, difficulty
7/13
Version: 29/August/2019
Consent Form

initials: _________
339 Windermere Road
London, Ontario, Canada N6A 5A5
Tel: (519) 685-8500 ext. 33631 • Fax: (519) 663-3753

99

breathing, feeling like you might pass out; seizure (convulsions); painful or difficult urination;
severe nausea, vomiting, or diarrhea; uneven heart rate or fluttering in your chest; confusion,
hallucinations, anxiety, agitation, depressed mood, thoughts of suicide or hurting yourself;
unusual or intense urges (e.g., gambling, sexual urges); chest pain or heavy feeling, pain
spreading to the arm or shoulder.
Experiments involving propranolol
You should not take propranolol if you have asthma. If you are a volunteer taking propranolol,
there is a potential risk of developing side effects following drug administration. More serious
side effects reported are based on chronic use of these medications in patients, and are not
expected to develop in this study given the single, low-dose of drug administered. Any side
effects that do occur are temporary and should quickly subside. In the unlikely situation that
your symptoms persist, you are invited to contact the experimenter to discuss your concerns.
Less serious side effects include: fatigue; nausea, vomiting, diarrhea, constipation, stomach
cramps; decreased sex drive, impotence, of difficulty having an orgasm; trouble concentrating,
sleep problems (insomnia). More serious side effects include: severe allergic reactions; fast,
slow, or uneven heartbeats; feeling light-headed or fainting; feeling short of breath even with
mild exertion; dilated neck veins, swelling of ankles or feet; nausea, upper stomach pain,
itching, loss of appetite, dark urine, clay-coloured stools, jaundice (yellowing of skin or eyes);
cool pale skin; cold feeling in hands or feet; depression, confusion, hallucinations, slurred
speech, headache; seizures; severe skin reaction (blistering or peeling skin)
Experiments involving polysomnographic sleep recording and electroencephalography
The only potential risk is for individuals with extremely sensitive skin. These individuals may
have a slight skin irritation where the skin has been gently exfoliated during electrode
application. When we apply the electrodes to the surface of the skin, we use a gentle,
hypoallergenic medical-grade exfoliant, called NuPrep, to clean the skin where the electrodes
will be placed. Any mild irritation to the skin normally lasts less than a few hours.
Experiments involving robotic arm manipulation
The principal potential risk is injury caused by the robotic arm. However, injury is very unlikely
and we have implemented a range of safety precautions that are widely used for the
prevention of injury in studies of human motor control involving robots. A number of safety
precautions have been implemented with respect to the robot linkage. In addition to
minimizing the applied force, we test for forces at the endpoint. If forces exceed 10 N all forces
are immediately set to zero. Additional vendor supplied algorithms limit the workspace over
which forces may be applied. Moreover, all experimental protocols were tested in full prior to
the experiment. Both you and the experimenter have a switch that instantaneously deactivates
the robot. In studies over the past 20 years using this setup at both Western and McGill we
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have not had a single injury or adverse event. The KINARM End-Point Lab is frequently used in
clinical populations with movement related disorders, and is marketed as an assessment tool in
these populations.
Experiments involving affective processing
There is the possibility of emotional and/or mental distress resulting from viewing images with
extremely graphic, violent, frightening, disturbing, and/or emotionally distressing content and
listening to sounds that portray equally upsetting or distressing emotional content. There is
also a small possibility that some of the recording electrodes may produce mild skin irritation.
Experiments involving virtual reality
Virtual reality can be disorienting and cause dizziness. The only potential risk is for individuals
to develop nausea and vomiting during the task. Before any testing begins, you will undergo a
period of acclimatization involving slow movements and interactions in the virtual environment
to ensure you are comfortable with performing the task.
Experiments involving driving simulation
Much like virtual reality, the driving simulator can also be disorienting that may lead to nausea
and vomiting. Before any testing begins, you will undergo a period of acclimatization involving
slow movements and interactions in the virtual environment to ensure you are comfortable
with performing the task.
Confidentiality
The investigators will maintain all information collected in this study strictly confidential, shared
only with individuals directly involved in this study, except as may be required by court order or by
law. To further ensure your confidentiality, information collected from you will be devoid of any
unique personal identifier and will be filed under an anonymous subject number. If any
publication or presentation results from this research, you will not be referred to by name and no
potentially identifying information will be released. The information collected in the course of this
study is kept on file in a secure location for no less than 25 years. If you decide you do not want
this information to be kept on file, simply advise the research team of your wishes, and your
record will be destroyed.
Your contact and demographic information collected for this study, will be stored in a secure,
password-protected database held at Western University. Only the researchers of this study and
the BrainsCAN coordinator, who administers the database system, will have access to your
identifiable information (e.g. name, date of birth, diagnoses, etc.). The BrainsCAN coordinator will
not need to review any of your information unless you have consented to be a part of the
OurBrainsCAN registry. If you agree to be a part of the OurBrainsCAN registry and have indicated
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that the researchers of this study can enter your identifiable information, they will include the
contact and demographic information collected for this study.
If you would like to be contacted about future research studies for which you (or your child) may
be eligible, you can choose to have your identifiable information entered into “OurBrainsCAN:
University of Western Ontario’s Cognitive Neuroscience Research Registry” by the researchers of
this study OR alternatively you can be given the web address of OurBrainsCAN where you are able
to enter your (or your child’s) information. This is a secure database of potential participants for
research at Western University, which aims to enrol 50,000 volunteers over a period of 5 years.
The information in this database will be stored indefinitely. The records are used only for the
purpose of recruiting research participants and will not be released to any third party. When you
are invited to participate future research studies, you will be given a full description of what your
involvement would entail. You are, of course, free to turn down any invitation. If, at any time, you
decide that you do not want your (your child’s) contact information to be a part of this database,
please contact ourbrains@uwo.ca to remove your information.
Consent to Use and Disclose Information for Research Subjects
Representatives of the University of Western Ontario Health Sciences Research Ethics Board
might be granted direct access to your medical records. A representative of the University of
Western Ontario Health Sciences Research Ethics Board might contact you or might require
access to your study-related records to monitor the conduct of the research. Similarly, as this
study is affiliated with Lawson Research, Lawson’s quality assurance and education may access
the study data for quality assurance purposes. By signing the consent, you also permit the
principal investigator to use and disclose health information about yourself for the purposes of
this study.
Incidental Findings
The tests you undergo in this study are not intended to diagnose or monitor any medical
conditions you may have. Nevertheless, if information that might be relevant to your care is
discovered incidentally, this information will be communicated to you, and at your request, to
your physician.
Compensation
You will receive $20-50 depending on the length (1.5hrs vs. 3hrs) and type (behavioural only vs.
behavioural with an MRI component) of study in which you are taking part. This is to
compensate you for the time and inconvenience associated with your participation. You will
also be reimbursed for parking costs.
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Voluntary Participation/Withdrawal from the Study
Your participation in this research is completely voluntary. You may refuse to continue
performing the tasks in this study at any time without any consequences. You may refuse to
participate, refuse to answer any questions or withdraw from the study at any time with no
effect on your future care. You do not waive any of your legal rights by signing the consent
form. If the research investigators find it necessary, and/or in your best interest, you will be
asked to withdraw from the study. In the event that you withdraw from the study for any
reason, you will receive compensation for the sessions that you attended, even if you did not
complete the entire session. Your cost of parking will also be reimbursed.
Contact Information
If you have any questions or concerns regarding the study, you may contact the principle
investigator. If you wish to speak to a neutral individual who is not involved in the study at all
and who will answer any questions about your rights as a research participant or about the
conduct of the study, you may contact a Patient Relations Specialist from London Health
Sciences Centre at 519-685-8500 ext. 52036.
Results
If you’re interested in obtaining the results of the study, we will gladly provide you with a
summary of our findings once the research is complete. Please let the investigator know if you
would like a summary of the results mailed or emailed to you.
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Consent Form
Distinguishing the roles of ventral and dorsal striatum in cognition
Principle Investigator: Penny A. MacDonald, MD, PhD
I (_________________________) have read the Letter of Information and Consent form and
have had the nature of the study explained to me and I agree to participate. All questions have
been answered to my satisfaction. I have been provided a copy of the Recruitment/Information
Letters and the Consent form. I freely and voluntarily consent to participate in this study.
_______________________________
Signature of participant

___________________
Date

Your signature on this form indicates that you are acting as a substitute decision maker(s) for
the participant and the study has been explained to you and all your questions have been
answered to your satisfaction. You agree to allow the person you represent to take part in the
study. You know that the person you represent can leave the study any time.
_______________________________
Signature of substitute decision maker
(if applicable)

___________________
Relationship to Participant

_______________________________
Signature of investigator

___________________
Date

___________________
Date

I have discussed this clinical research study with the participant using a language that is
understandable and appropriate. I believe that I have fully informed this participant of the purpose,
duration etc. of this research study and its possible benefits and risks and I believe the participant
understood this explanation.
_______________________________________
Signature of person assisting in consent process

________________________
Date
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Optional Consent to be Added to OurBrainsCAN Recruitment Database
I consent to being added to the OurBrainsCAN: University of Western Ontario’s Cognitive
Neuroscience Research Registry to be contacted about future research studies for which I (or
my child) may be eligible:
Please initial:
________ Yes, I already signed-up.
________ Yes, the researcher can enter my information into the database on my behalf.
________ Yes, please provide me the link to join the database myself.

Participant’s Name (Please print): ____________________________________

Participant’s Signature: ____________________________________

Date: ____________________________________
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Appendix C: Ethics Approval
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Appendix D: Epworth Sleepiness Scale
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Appendix E: Barratt Impulsiveness Scale

For administrator’s use only
Score:
Sub-scores: A:

CI:

M:

Date (dd/mm/yy):
Subject #:
Medication:
SC:
CC:

P:

Session #:
Time:

Barratt Impulsiveness Scale (BIS-11)
Directions: People differ in the ways they act and think in different situations. This is a test to
measure some of the ways in which you act and think. Read each statement and put an X on
the appropriate circle on the right side of this page. Do not spend too much time on any
statement. Answer quickly and honestly.
1

2

3

Rarely/Never
Occasionally
Often
1. I plan tasks carefully.
2. I do things without thinking.
3. I make-up my mind quickly.
4. I am happy-go-lucky.
5. I don’t “pay attention.”
6. I have “racing” thoughts.
7. I plan trips well ahead of time.
8. I am self-controlled.
9. I concentrate easily.
10. I save regularly.
11. I “squirm” at plays or lectures.
12. I am a careful thinker.
13. I plan for job security.
14. I say things without thinking.
15. I like to think about complex problems.
16. I change jobs.
17. I act “on impulse.”
18. I get easily bored when solving thought problems.
19. I act on the spur of the moment.
20. I am a steady thinker.
21. I change residences.
22. I buy things on impulse.
23. I can only think about one thing at a time.
24. I change hobbies.
25. I spend or charge more than I earn.
26. I often have extraneous thoughts when thinking.
27. I am more interested in the present than the future.
28. I am restless at the theatre or lectures.
29. I like puzzles.
30. I am future oriented.
Patton, Stanford, Barratt (1995), J Clin Psy, vol. 51, pp. 768-774

4

Almost Always/Always
1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3
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1
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3
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Appendix F: Oxford Happiness Questionnaire
For$administrator’s$use$only
Score:

Date1(dd/mm/yy):
Subject1#:
Medica, on:

Session:
Time:

Oxford Happiness Questionnaire
The Oxford Happiness Questionnaire was developed by psychologists Michael Argyle and Peter Hills at
Oxford University.
Instructions
Below are a number of statements about happiness. Please indicate how much you agree or disagree
with each by entering a number in the blank after each statement, according to the following scale:
1 = strongly disagree
2 = moderately disagree
3 = slightly disagree
4 = slightly agree
5 = moderately agree
6 = strongly agree
Please read the statements carefully, some of the questions are phrased positively and others
negatively. Don’t take too long over individual questions; there are no “right” or “wrong” answers (and
no trick questions). The first answer that comes into your head is probably the right one for you. If you
find some of the questions difficult, please give the answer that is true for you in general or for most of
the time.
The Questionnaire
1. I don’t feel particularly pleased with the way I am. ( R) ______
2. I am intensely interested in other people. _____
3. I feel that life is very rewarding. _____
4. I have very warm feelings towards almost everyone. _____
5. I rarely wake up feeling rested. (R) _____
6. I am not particularly optimistic about the future. (R) _____
7. I find most things amusing. _____
8. I am always committed and involved. _____
9. Life is good. _____
10. I do not think that the world is a good place. (R) _____
11. I laugh a lot. _____
12. I am well satisfied about everything in my life. _____
13. I don’t think I look attractive. (R) _____
14. There is a gap between what I would like to do and what I have done. (R) _____
15. I am very happy. _____
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Appendix G: Questionnaire for Impulsive-Compulsive Disorders in
Parkinson’s Disease – Rating Scale
Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale
(QUIP-RS)
Reported by:

_____ Patient

_____ Informant

Patient / Subject:

__________________________________________

Date:

__________________________________________

_____ Patient and Informant

1. How much do you think about the following behaviors (such as having trouble keeping thoughts out of your mind or
feeling guilty)?
Gambling?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)
Sex?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Buying?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Eating?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Performing tasks or hobbies? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Repeating simple activities?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)
Taking your PD medications? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
2. Do you have urges or desires for the following behaviors that you feel are excessive or cause you distress (including
becoming restless or irritable when unable to participate in them)?
Gambling?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)
Sex?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Buying?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Eating?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Performing tasks or hobbies? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Repeating simple activities?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)
Taking your PD medications? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
3. Do you have difficulty controlling the following behaviors
down or stopping them)?
Gambling?
___Never(0) ___Rarely(1)
Sex?
___Never(0) ___Rarely(1)
Buying?
___Never(0) ___Rarely(1)
Eating?
___Never(0) ___Rarely(1)
Performing tasks or hobbies? ___Never(0) ___Rarely(1)
Repeating simple activities?
___Never(0) ___Rarely(1)
Taking your PD medications? ___Never(0) ___Rarely(1)

(such as increasing them over time, or having trouble cutting
___Sometimes(2)
___Sometimes(2)
___Sometimes(2)
___Sometimes(2)
___Sometimes(2)
___Sometimes(2)
___Sometimes(2)

___Often(3)
___Often(3)
___Often(3)
___Often(3)
___Often(3)
___Often(3)
___Often(3)

___Very often(4)
__ _Very often(4)
__ _Very often(4)
__ _Very often(4)
__ _Very often(4)
___Very often(4)
__ _Very often(4)

4. Do you engage in activities specifically to con tinue the following behaviors (such as hiding what you are doing, lying,
hoarding things, borrowing from others, accumulating debt, stealing, or being involved in illegal acts)?
Gambling?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)
Sex?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Buying?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Eating?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Performing tasks or hobbies? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
Repeating simple activities?
___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)
Taking your PD medications? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very often(4)
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Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale
(QUIP-RS)
Subject:

__________________________________________

Date:

__________________________________________

SCORING SHEET
A. Gambling

______

(0-16)

B. Sex

______

(0-16)

C. Buying

______

(0-16)

D. Eating

______

(0-16)

E. Hobbyism-Punding

______

(0-32)

F. PD Medication Use

______

(0-16)

Total ICD Score (A-D)

______

(0-64)

Total QUIP-RS Score (A-F)

______

(0-112)

QUIP-RATING SCALE
Version 1.0 (7/01/09)
Copyright © University of Pennsylvania 2009
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Appendix H: Verbal and Category Fluency
For administrator’s use only
Score:

Date (dd/mm/yy):
Subject #:
Medication:

Session #:
Time:

Verbal Fluency
Instructions: I will say a letter of the alphabet. Then I want you to give me as many words that begin
with that letter as quickly as you can. For instance, if I say “B”, you might give me “bad”, “battle”, or
“bed.” I do not want you to use words that are proper names such as “Boston” or “Bob.” Also, do not
use the same word again with a different ending such as “eat” and “eating.” Any questions? Begin when
I say the letter. The first letter is “F”. Go Ahead. Begin timing immediately. Mark 30 seconds.

Category Fluency
Instructions: I now want you to name as many animals as you can, as quickly as you can. These can be
animals that live in water or on land. Any questions? Begin timing immediately. Mark 30 seconds. If
necessary, give the example that a dolphin lives in water and a dog lives on land.
F

A

S

Animals
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Appendix I: Sensation Seeking Scale
For administrator’s use only
Total:

BS:

D:

ES:

TAS:

Date (dd/mm/yy):
Subject #:
Medication:

Session #:
Time:

Sensation Seeking Scale Form V
Instructions: Each of the items below contains two choices, A and B. Please indicate (circle) on your
answer sheet which of the choices most describes your likes or the way you feel. In some cases you may
find items in which both choices describe your likes or feelings. Please choose the one which better
describes your likes or feelings.
In some cases you may find items in which you do not like either choice. In these cases mark the choice
you dislike least. Please answer each item.
It is important you respond to all items with only one choice, A or B. We are interested only in your likes
or feeling, not in how others feel about these things or how one is supposed to feel. There are no right or
wrong answers as in other kinds of tests. Be frank and give your honest appraisal of yourself.
1. A. I like “wild” uninhibited parties

10.

effects on me

2. A. There are some movies I enjoy seeing a

B. I would like to try some of the new drugs

second or even a third time
B. I can’t stand watching a movie that I’ve seen
before

that produce hallucinations
11.

B. I sometimes like to do things that are a

B. I can’t understand people who risk their necks

4. A. I dislike all body odors

little frightening
12.

B. I enjoy the company of real “swingers”
13.

B. I like to comfortable familiarity of everyday

B. I often like to get high (drinking liquor or
smoking marijuana)

6. A. I like to explore a strange city or section of
14.

B. I prefer a guide when I am in a place I don’t

B. I order the dishes with which I am familiar,
so as to avoid disappointment and

7. A. I dislike people who do or say things just to

unpleasantness

shock or upset others
15.

person will do and say he or she must be a

B. Looking at someone’s home movies or
travel slides bores me tremendously

8. A. I usually don’t enjoy a movie or play where I
16.

B. I don’t mind watching a movie or a play where

B. I would never smoke marijuana

A. I would like to take up the sport of water
skiing

I can predict what will happen in advance
9. A. I have tried marijuana or would like to

A. I enjoy looking at home movies or travel
slides

bore

can predict what will happen in advance

A. I like to try new foods that I have never
tasted before

know well

B. When you can predict almost everything a

A. I find that stimulants make me
uncomfortable

friends

town by myself, even if it means getting lost

A. I dislike “swingers” (people who are
uninhibited and free about sex)

B. I like some for the earthly body smells
5. A. I get bored seeing the same old faces

A. A sensible person avoids activities that are
dangerous

3. A. I often wish I could be a mountain climber
climbing mountains

A. I would not like to try any drug which
might produce strange and dangerous

B. I prefer quiet parties with good conversation

B. I would not like to take up water skiing
17.

A. I would like to try surf boarding
B. I would not like to try surf boarding
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18.

A. I would like to take off on a trip with no

30.

preplanned or definite routes, or timetable

because some people get loud and
boisterous

B. When I go on a trip I like to plan my route
and timetable fairly carefully
19.

B. Keeping the drinks full is the key to a good
party

A. I prefer the “down to earth” kinds of people
as friends

31.

B. I would like to make friends in some of the
“far out” groups like artists or “punks”
20.

32.

A. I would not like to learn to fly an airplane

experience before marriage
their sexual experience with each other
33.

in the “jet set”

A. I would like to meet some persons who are

B. I could conceive of myself seeking

homosexual (men or women)

pleasures around the world with the “jet

B. I stay away from anyone I suspect of being
“gay or lesbian”
23.

A. I would like to try parachute jumping

set”
34.

B. I dislike people who have their fun at the

plane with or without a parachute
A. I prefer friends who are excitingly
unpredictable

expense of hurting the feelings of others
35.

B. I enjoy watching many of the “sexy” scenes

predictable
A. I am not interested in experience for its
own sake

in movies
36.

frightening, unconventional, or illegal
26.

liquor to feel good
37.

B. People should dress in individual ways even

symmetry of form and harmony of colors
and irregular forms of modern paintings
27.

if the effects are sometimes strange
38.

B. I would like to sail a long distance in a

surroundings of home
home for any length of time
28.

small but seaworthy sailing craft
39.

B. I find something interesting in almost every

B. I don’t like the feeling I get standing on the

29.

A. I like to date members of the opposite sex
who are physically exciting
B. I like to date members of the opposite sex
who share my values

A. I have no patience with dull or boring
persons

A. I like to dive off the high board
high board (or I don’t go near it at all)

A. Sailing long distances in small sailing crafts
is foolhardy

A. I enjoy spending time in the familiar
B. I get very restless if I have to stay around

A. People should dress according to some
standard of taste, neatness, and style

A. The essence of good art is in its clarity,
B. I often find beauty in the “clashing” colors

A. I feel best after taking a couple of drinks
B. Something is wrong with people who need

B. I like to have new and exciting experiences
and sensations even if they are a little

A. There is altogether too much portrayal of
sex in movies

B. I prefer friends who are reliable and

25.

A. I like people who are sharp and witty even
if they do sometimes insult others

B. I would never want to try jumping out of a

24.

A. Even if I had the money I would not care to
associate with flight rich persons like those

B. I would like to go scuba diving
22.

A. A person should have considerable sexual
B. It’s better if two married persons begin

A. I prefer the surface of the water to the
depths

A. The worst social sin is to be rude
B. The worst social sin is to be a bore

B. I would like to learn to fly an airplane
21.

A. Heavy drinking usually ruins a party

person I talk to
40.

A. Skiing down a high mountain slope is a
good way to end up on crutches
B. I think I would enjoy the sensations of
skiing very fast down a high mountain
slope
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Appendix J: New Freezing of Gait Questionnaire

New Freezing of Gait Questionnaire
Part I – Distinction Freezer – non-Freezer, over the past month
1. Did you experience “freezing episodes” over the past month?
Without video
Freezing is the feeling that your feet are transiently glued to the floor while trying to initiate
walking, making a turn or when walking through narrow spaces or in crowded places?
Sometimes it can be accompanied with trembling of the legs and small shuffling steps.
Additional instructions with video
We will watch a short video together to see the many ways in which freezing can occur. Also, look carefully for how long these episodes
last, as you can expect some questions on this later. (tester points out the clock on video clip)
0. I have not experienced such a feeling or episode over the past month
1. I have experienced such a feeling or episode over the past month

If the answer is 1 (patient is a freezer) complete part II and III. The sum of part II and III
is the final NFOG score.
Part II – Freezing severity
2.

How frequently do you experience freezing episodes?
0. Less than once a week
1. Not often, about once a week
2. Often, about once a day
3. Very often, more than once a day

3. How frequently do you experience freezing episodes during turning?
0. Never
1. Rarely, about one a month
2. Not often, about once a week
3. Often, about once a day
4. Very often, more than once a day
If the answer is 1 or more go to question #4. If the answer is 0, go directly to #5.
4. How long is your longest freezing episode during turning?
1. Very short, 1 sec
2.

Short, 2 - 5 s.

3. Long, between 5 and 30 s.
4. Very long, unable to walk for more than 30 s.
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Appendix K: Montreal Cognitive Assessment
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Appendix L: American National Adult Reading Test

ANART
1.

ache

22. chamois

43. cabal

2.

debt

23. papyrus

44. apropos

3.

pint

24. asthma

45. caprice

4.

depot

25. hiatus

46. demesne

5.

chord

26. simile

47. imbroglio

6.

bouquet

27. blatant

48. hyperbole

7.

deny

28. cellist

49. syncope

8.

capon

29. zealot

50. prelate

9.

heir

30. abstemious

10. aisle

31. meringue

11. subtle

32. placebo

12. nausea

33. façade

13. gauge

34. pugilist

14. naïve

35. virulent

15. thyme

36. worsted

16. courteous

37. détente

17. algae

38. anise

18. fetal

39. sieve

19. quadruped

40. chassis

20. epitome

41. beatify

21. superfluous

42. scion
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For administrator’s use only
Score:

Date (dd/mm/yy):
Subject #:
Group:

Session #:
Time:

ANART Score Sheet
1. ache

_______ (eyk)

2. debt

_______ (det)

3. pint

_______ (pahynt)

4. depot

_______ (dee-poh)

5. chord

_______ (kawrd)

6. bouquet

_______ (boh-kay)

7. deny

_______ (dih-nahy)

8. capon

_______ (kay-pon)

9. heir

_______ (air)

10. aisle

_______ (ahyl)

11. subtle

_______ (suht-l)

12. nausea

_______ (naw-zee-uh)

13. gauge

_______ (geyj)

14. naïve

_______ (nah-eev)

15. thyme

_______ (time)

16. courteous

_______ (kur-tee-uhs)

17. algae

_______ (al-jee)

18. fetal

_______ (feet-l)

19. quadruped

_______ (kwod-roo-ped)

20. epitome

_______ (ih-pit-uh-mee)

21. superfluous

_______ (soo-pur-floo-uhs)

22. chamois

______(sham-ee, sha-mwah)

23. papyrus

_______ (puh-pahy-ruhs)

24. asthma

_______ (az-muh)

25. hiatus

_______ (hahy-ey-tuhs)

26. simile

_______ (sim-uh-lee)

27. blatant

_______ (bleyt-nt)

28. cellist

_______ (chel-ist)

29. zealot

_______ (zel-uht)

30. abstemious

_______ (ab-stee-mee-uhs)

31. meringue

_______ (muh-rang)

32. placebo

_______ (pluh-see-boh)

33. façade

_______ (fuh-sahd)

34. pugilist

_______ (pyoo-juh-list)

35. virulent

_______ (vir-yuh-luhnt)

36. worsted

_______ (woos-tid, wur-stid)

37. détente

_______ (dey-tahnt)

38. anise

_______ (an-is)

39. sieve

_______ (siv)

40. chassis

_______ (chas-ee)

41. beatify

_______ (bee-at-uh-fahy)

42. scion

_______ (sahy-uhn)

43. cabal

_______ (kuh-bal)

44. apropos

_______ (ap-ruh-poh)

45. caprice

_______ (kuh-prees)

46. demesne

_______ (dih-meyn)

47. imbroglio

_______ (im-brohl-yoh)

48. hyperbole

_______ (hahy-pur-buh-lee)

49. syncope

_______ (sing-kuh-pee)

50. prelate

_______ (prel-it)
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Appendix M: Bond & Ladder Visual Analogue Mood Scale

For administrator’s use only
Score:

Date (dd/mm/yy):
Subject #:
Medication:

Session #:
Time:

Bond & Lader Visual Analogue Mood Scale - PRE
Instructions: For each line below, put a vertical mark at the point that represents how you feel at this
moment. Ensure to draw your line all the way through the horizontal line. The ends of each scale are to
present the “most” that you have ever felt in your life.
ALERT

DROWSY

_______ mm

CALM

EXCITED

_______ mm

FEEBLE

_______ mm

CLEAR HEADED

_______ mm

CLUMSY
EXTRAEXTRA

_______ mm
EXTRAEXTRA

ENERGETIC

_______ mm

DISCONTENTED

_______ mm

TROUBLED

TRANQUIL

_______ mm

MENTALLY
SLOW

QUICK WITTED
EXTRAEXTRA

_______ mm
EXTRAEXTRA

TENSE

RELAXED

_______ mm

ATTENTIVE

DREAMY

_______ mm

PROFICIENT

_______ mm

SAD

_______ mm

FRIENDLY

_______ mm

BORED

_______ mm

SOCIABLE

_______ mm

STRONG
MUZZY
WELL
COORDINATED
LETHARGIC
CONTENDED

INCOMPENTENT
HAPPY
ANTAGONISTIC
INTERESTED
WITHDRAWN
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Appendix N: Starkstein Apathy Scale

For administrator’s use only
Score:

Date (dd/mm/yy):
Subject #:
Group:

Session #:
Time:

Starkstein Apathy Scale
Instructions: For each question, indicate as “Not at all”, “Slightly”, “Some”,
or “A lot” with an ‘X’ while leaving the other spaces blank.
Questions
1. Are you interested in
learning new things?
2. Does anything interest you?
3. Are you concerned about
your condition?
4. Do you put much effort into
things?
5. Are you always looking for
something to do?
6. Do you have plans and goals
for the future?
7. Do you have motivation?
8. Do you have the energy for
daily activities?
9. Does someone have to tell
you what to do each day?
10. Are you indifferent to
things?
11. Are you unconcerned with
many things?
12. Do you need a push to get
started on things?
13. Are you neither happy nor
sad, just in between?
14. Would you consider
yourself apathetic?

Not at all

Slightly

Some

A lot
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